DAX+0,68 % EUR/USD-0,21 % Gold-0,20 % Öl (Brent)-0,21 %

onyx pharmaceut. im juhu musterdepot! - 500 Beiträge pro Seite


AnzeigeAdvertisement

Beitrag schreiben

Begriffe und/oder Benutzer

 

hab mich entschloßen,auch mal einen biotechwert zu kaufen,leider kenn ich mich nicht so gut aus,auf juhu.de biotech musterdepot haben die werte eine tolle performance ,aber onxx lief noch nicht ,deshalb überlege ich einzusteigen,was hält ihr von diesem wert?
Verfolge seit längerem die Juchu Musterdpots und habe teilweise gleichgezogen.
JUCHU !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

kann man da nur sagen.
MfG
Hallo Panik,
habe diese Aktie seit Wochen beoabachtet und hätte sie im Jan kaufen sollen, denn da war das gute Stück nur
14 Euro. Im Zuge der allgemeinen Biotechmanie sind diese ebenfalls mit angesprungen. Im neuen Finanzen Magazin
ist bzw. sind alle Biotechs aufgelistet unter anderem auch Onyx. Am Besten fährt man allerdings mit einem Fonds
man kann als Laie nicht alle Werte kennen bzw. deren Risiko. Persönlich denke ich das evt. auch mit einerweiteren Korrektur
bei den Biotechs zu rechnen ist, dann wäre ein Einstieg aber nur in die bereits etablierten Bios ratsam.
Ich überlege mir auch einzusteigen! Hat jemand die Wkn?
Was machen die überhaupt, daß die so empfohlen werden?
Stormman :)
Hallo Stormman,

WKN: 900778

Entwickelt Krebs-Therapien auf Basis der Gentechnik. Präparat Onyx-015 kurz vor Markreife (Quelle: Finanzen 04/April S. 39).
Überlege mir auch in diesen Wert einzusteigen. Interessiere mich auch noch für Guilford Pharmac. und Boston Life Scienc.
Wer hier noch interessante Infos hat, soll doch bitte antworten.

Gruß
Auch ich bin ziemlich bullish für diesen Wert, zumal er jetzt auch die Atmerksamkeit bekommt, die er verdient (juchu + global biotech investor). ONYX-15 soll übrigens Hautkrebs bekämpfen.
Hallo Biotech-Freunde !!!!
Meine Meinung zu Onyx?? Heute ist der Kurs bei ca. 17 Euro !!!
Wer jetzt nicht keuft ist selber Schuld. Laut meinen Infos steht das Krebsmittel kurz vor dem Durchbruch !!
Solange Bill Clinton nichts Negatives mehr über Biotech sagt, setzte ich das Kursziel auf mindestens 35 Euro.
Also, STRONG BUY !!!!!
Gruß
is ja auch lang genug her...halte diesen antikörper für den besten auf dem markt, da er kranke krebszellen abtötet (rückbildung 100 %- einmalig) ohne gesundes gewebe anzugreifen, tests für verschiedenste krebsarten laufen. noch keiner wurde negativ abgebrochen, wieder mal Sammelzeit. 10 $ sollten aber halten.
Onyx and XOMA Announce Strategic Process Development and Manufacturing Agreement
RICHMOND, Calif., Jan. 29 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced that it has entered into a strategic process development and manufacturing relationship with XOMA (US) LLC (Nasdaq: XOMA - news) of Berkeley, California. Under the terms of the multiyear agreement, XOMA will develop a large-scale process and will manufacture CI-1042 (ONYX-015) for clinical trials and large-scale production. In return, Onyx will provide XOMA with an upfront payment; support for development efforts on the process scale-up and production of bulk drug materials; and milestone payments associated with attainment of large-scale production.

``We are delighted to have the opportunity to work with XOMA, one of the most experienced companies in process development and large-scale manufacturing of biopharmaceuticals,`` said Hollings C. Renton, Chairman of the Board, President and Chief Executive Officer of Onyx Pharmaceuticals, Inc. ``The agreement allows us to increase the supply of CI-1042 for our various clinical trials and for commercial launch of CI-1042 under our collaboration with Pfizer. XOMA will develop a large-scale manufacturing process for CI-1042 based on our current process.``

``We are looking forward to this opportunity to work with Onyx on their innovative viral therapy for cancer,`` said Jack Castello, Chairman of the Board, President and CEO of XOMA. ``With XOMA`s experience and infrastructure, we believe we can move quickly to scale-up production of CI-1042, to enhance the manufacturability, and cost structure of the product.``

CI-1042 is a tumor-selective, modified adenovirus (a type of virus that can cause a common cold) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway while sparing normal cells which have (functioning) p53 protein. p53, a protein that protects the cell from developing into a tumor cell, is the most commonly altered gene in human cancer. CI-1042 is being jointly developed by Onyx Pharmaceuticals and Pfizer Inc under an agreement signed in October 1999.

CI-1042, now in a Phase III clinical trial and various Phase I/II trials, is currently being manufactured using a small-scale process. Due to the limitation of the scale and the ability to produce less than sufficient quantities of materials for multiple clinical trials, Onyx and Pfizer have had to prioritize which clinical trials receive materials. The Phase II clinical trials where the drug is administered intravenously received a preferential supply of materials over the Phase III clinical trial. As a result, the accrual of clinical sites and the enrollment of patients in the Phase III study in recurrent Head and Neck cancer had been slowed. To date, drug supplies have been available to two clinical sites. Currently, there are 10 clinical sites open for patient enrollment.

``Our current contract manufacturers have implemented plans to increase the supplies of CI-1042,`` said Hollings C. Renton. ``With these actions and the new support from XOMA, we believe that we can increase the accrual of the clinical trials in an attempt to minimize any potential delay in timelines to launch.``

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on our proprietary virus technologies, we are developing our lead product, CI-1042. CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

XOMA develops and manufactures antibody and other protein biopharmaceuticals for disease targets that include immunological and inflammatory disorders, infectious diseases and cancer. Late-stage programs include collaboration with Genentech, Inc. to develop the anti-CD11a antibody product for psoriasis (Phase III) and kidney transplant rejection (Phase I/II), and an agreement with the Hyland Immuno Division of Baxter Healthcare Corporation to develop NEUPREX® (a systemic formulation of rBPI21) for multiple indications. Earlier stage products include ING-1, Genimune (TM), Mycoprex (TM) and antiangiogenic compounds. For more information about XOMA`s pipeline and activities, visit XOMA`s web site at www.xoma.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
WHAT: Onyx Phamaceuticals, Inc. (Nasdaq: ONXX - news) to present on progress

with its novel lead product, CI-1042 (ONYX-015), for treatment

of head and neck cancer, and its other products in clinical

development at the Biotechnology Industry Organization (BIO) CEO

& Investor Conference 2001 in New York, NY.


The presentation will be web cast for investors from the
following site:

http://www.informedinvestors.com/iif_forums/event.cfm?forumID=153 .

The Onyx presentation will be available "real-time" over the
Internet; click on the above link and scroll to "click to
listen" opposite Onyx (listed under company names); replay will
be available for up to 90 days.

WHO: Hollings C. Renton, Chairman and Chief Executive Officer of
Onyx, Member of BIO`s Board of Directors

WHEN: Wednesday, February 21, 2001 at 9:30 a.m. EST

WHERE: BIO CEO & Investor Conference 2001
The Waldorf-Astoria
Basildon Room
301 Park Avenue
New York, NY 10022

Contact: Helen Kim, 510-262-8737, ir@onyx-pharm.com
Betsy Rosenberg, 415-221-6854, bprcomm@yahoo.com


About Onyx

Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015), a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway function, while sparing normal cells that have normal p53 pathway function. p53 is the most common genetically altered protein in human cancer. CI-1042 (ONYX-015) is being jointly developed by Onyx and Pfizer Inc. (NYSE: PFE - news). CI-1042 (ONYX-015) is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 (ONYX-015) and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals Announces Conference Call to Report Financial Results Of Fourth Quarter and Fiscal Year 2000
RICHMOND, Calif., Feb. 22 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced that it will host a conference call on Wednesday, February 28, 2001, at 4:30 p.m. EST, to discuss the financial results of the fourth quarter and fiscal year 2000. Hollings C. Renton, Chairman and Chief Executive Officer will host the call.

To access the conference call, dial 800-498-2168 (within the United States), or 706-634-6592 (if calling from outside the U.S.). An audio replay will be available two hours after the completion of the call through March 14 and can be accessed by dialing 800-642-1687, identification number 280100. A webcast will also be available at www.presentonline.com; click on conference archives and enter identification number x96857.

Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015), a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and kill cancer cells that have abnormal p53 pathway function while sparing normal cells. CI-1042 is currently being evaluated in a Phase III clinical trial for head and neck cancer, and is in Phase I and II clinical trials for a number of additional cancer indications. CI-1042 is being jointly developed by Onyx with Warner-Lambert, a subsidiary of Pfizer Inc.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Reports Fourth Quarter and Year-End 2000 Financial Results
RICHMOND, Calif., Feb. 28 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the results of operations for the fourth quarter and year ended December 31, 2000.

The company reported a net loss of $3,333,000, or $0.19 per share for the fourth quarter ended December 31, 2000 compared with a net loss of $1,647,000, or $0.14 per share for the same quarter in 1999. For the year ended December 31, 2000, the company reported a net loss of $7,479,000, or $0.50 per share, compared with a net loss of $14,802,000, or $1.29 per share, for the same period in 1999.

For the quarters ended December 31, 2000 and 1999, total revenue was $4,338,000 and $6,601,000, respectively. Revenue decreased in the quarter ended December 31, 2000 by $2,263,000 over the same period last year. In December 1999, the company recognized $1,589,000 related to the final research payment from its collaboration with Bayer Corporation. The company is now co-developing a clinical candidate with Bayer. The remainder of the difference pertained to a decrease in CI-1042 (ONYX-015) development cost reimbursement revenue from Warner-Lambert Company during 2000 as Warner-Lambert has assumed the management over clinical trials. Revenue for both quarters also included amounts earned for research performed under our collaborations with Warner-Lambert for the cell cycle and inflammation programs.

Total operating expenses for the quarters ended December 31, 2000 and 1999 were $8,884,000 and $8,419,000, respectively. During the quarter ended December 31, 2000 as compared to the same period in the prior year, development expenses related to the co-development of a clinical candidate with Bayer increased and were offset by a decrease in CI-1042 clinical trial expenses as these costs were assumed by Warner-Lambert. General and administrative expenses increased due to the hiring of additional staff to support our research and development efforts.

For the years ended December 31, 2000 and 1999, total revenue was $24,180,000 and $13,324,000, respectively. This revenue represents amounts earned for research performed under the company`s collaborations. The increase in revenue in 2000 is due primarily to the collaboration agreement with Warner-Lambert, effective as of September 1999, to develop and commercialize CI-1042 as well as two additional product candidates, including a $3,700,000 payment received upon the completion of a research milestone in the quarter ended June 30, 2000.

Total operating expenses in 2000 of $34,387,000 were $5,419,000 greater than in 1999. This increase was primarily attributable to manufacturing expenses associated with the CI-1042 Phase III clinical trials and various Phase I/II clinical trials. Additionally, a Phase I clinical trial of the raf kinase inhibitor was initiated with Bayer in the quarter ended September 30, 2000, and Onyx is co-funding clinical development costs. Also, hiring additional staff contributed to the increase in operating expenses in 2000.

As of December 31, 2000, the company had cash, cash equivalents and short-term investments of $81,994,000. The company completed two private placements of 2,279,470 shares of common stock in the quarter ended March 31, 2000 and a follow-on equity offering of 3,450,000 shares of common stock in October 2000 that raised aggregate net proceeds of $71,000,000.

``We are pleased with the significant progress made by Onyx in 2000,`` said Hollings Renton, Chairman and Chief Executive Officer of Onyx. ``The initiation of a Phase III clinical trial for Onyx`s lead product, CI-1042, for the treatment of recurrent head and neck cancer as well as the initiation of Phase I clinical testing for the company`s novel oral raf kinase inhibitor, known as BAY 43-9006, represent major milestones for the company. Additionally, the development and manufacturing relationship that we entered into with XOMA in January 2001 will enable us to increase supply of CI-1042 for our various clinical trials under our collaboration with Warner-Lambert and provide supply for commercial use.``

Onyx will host a conference call today, Wednesday, February 28, 2001 at 1:30 p.m. PST/ 4:30 p.m. EST to discuss the results of the fourth quarter and year-end 2000 financials. To participate in the conference call, dial 800-498-2168 (within the United States) or 706-634-6592 (if calling from outside the U.S.).

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.


ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Months Ended Year Ended
December 31, December 31,
2000 1999 2000 1999

Total revenue $4,338 $6,601 $ 24,180 $13,324
Operating expenses:
Research and development 6,939 7,079 26,879 23,627
General and administrative 1,945 1,340 7,508 5,341
Total operating expenses 8,884 8,419 34,387 28,968
Loss from operations (4,546) (1,818) (10,207) (15,644)
Interest income, net 1,213 171 2,728 842
Net loss $(3,333)
$ (1,647) $(7,479) $(14,802)
Basic and diluted net loss
per share $(0.19) $(0.14) $(0.50) $(1.29)
Shares used in computing basic
and diluted net loss per share 17,458 11,536 14,896 11,503


CONDENSED BALANCE SHEETS
(in thousands)
Dec. 31, Dec. 31,
2000 1999
(unaudited) (1)
Assets
Cash, cash equivalents and
short-term investments $81,994 $14,463
Other current assets 3,083 3,760
Total current assets 85,077 18,223
Property and equipment, net 3,132 3,000
Other assets 388 405
Total assets $88,597 $21,628

Liabilities and stockholders` equity
Current liabilities $10,868 $11,450
Long-term obligations 833 2,516
Stockholders` equity 76,896 7,662
Total liabilities and stockholders`
equity $88,597 $ 21,628

Derived from the audited financial statements included in the Company`s
Annual Report on Form 10-K for the year ended December 31, 1999.

SOURCE: Onyx Pharmaceuticals, Inc.
Ich würde es besser finden, diese Nachrichten zu kommentieren, statt nur die News, die eh jeder Shareholder verfolgt, hier zu posten. Der Umsatz- und Ertragsstrom aus CI-1042 ist in greifbarer Nähe. Nach der Koorperation mit Xoma dürfte es bald so weit sein. Dann werden die alten Höhen übertroffen werden... Die Mcap von unter 200 Mio. ist schlichtweg ein Witz. Offensichtlich kennen viele potentiellen Investoren micht die Ergebnisse von CI-1042 aus den klinischen Tests, geschweige denn von den Nachfolgeprodukten...

Viel Glück
Mr. Salami
USB Piper Jaffray - Strong buy - Target 30 $ (!!!)

...anscheinend hat`s doch jemand gemerkt.

Mr. Salami
Onyx Pharmaceuticals* Symbol Rating Price Mkt. Cap. ༼EQ ༽E Pr. Target ONXX Neutral $10 1/2 $188 $(0.50) $(1.47)) $10 HEADLINE: Onyx Reports Earnings We are maintaining our Neutral rating and $10 target price
Xenogen Enters into Evaluation License Agreement with Onyx Pharmaceuticals
- Xenogen`s Technology to be Used in Cancer Drug Discovery Programs-
ALAMEDA, Calif., March 8 /PRNewswire/ -- Xenogen Corporation today announced that it has entered into a six-month evaluation license agreement with Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) for Xenogen`s proprietary real-time, in vivo imaging technology. Onyx intends to use Xenogen`s technology to image bioluminescent cancer cells in vivo for their virus research programs. Onyx will also use Xenogen`s technology to image and study the biological activity of viruses that have been genetically engineered to selectively replicate in and lyse (burst) cancer cells.

``This is yet another great new collaboration with a biotech company, where we believe Xenogen`s technology will add value to their drug discovery programs``, said Pamela Reilly Contag, Ph.D., president and co-CEO of Xenogen Corporation. ``Onyx Pharmaceuticals is working on some highly innovative cancer therapies and we are excited that our technology will aid in this endeavor.``

Xenogen`s technology represents a unique and novel approach to the biological assessment of new chemical entities (NCEs) by enabling the detection of fluorescent or bioluminescent cells (e.g. tumor cells, bacteria) in living animals. This not only allows for non-invasive visualization and tracking of cells to monitor NCE efficacy in real time, but also provides researchers with methods to localize and follow the activation of selected genes in vivo via Xenogen`s LPTA(TM) transgenic animals. The key advantage to Xenogen`s methods is the provision of high-quality data at earlier time points, thus accelerating the discovery of NCE`s, while providing real savings in the time and cost of drug development.

Xenogen has recently entered into a series of agreements with leading pharmaceutical and biotechnology companies. Recent Xenogen milestones include the granting of a commercial license to a company of Novartis Research Foundation and the granting of evaluation licenses to AstraZeneca, Cell Genesys, Chiron, Cubist Pharmaceuticals, DuPont Pharmaceuticals and Organon.

About Onyx Pharmaceuticals Inc.

Onyx Pharmaceuticals is engaged in the discovery and development of novel, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing CI-1042 (ONYX-015) as its lead product. CI-1042 is a therapeutic tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway function while sparing normal cells that have functioning p53. Such abnormalties in the p53 protein pathway are the most common genetic aberrations in human cancer. CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications. For more information about Onyx, visit the company`s web site at http://www.onyx-pharm.com.

About Xenogen Corporation

Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with proprietary technologies, products and services to enable real-time in vivo monitoring to identify drug leads for clinical development. In addition to pharmaceutical development, Xenogen believes that its technology has broad applications in other fields, including biomedical research and toxicology testing in the chemical industry.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including risks cited in the risk factors sections of Xenogen`s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Xenogen disclaims and intent or obligation to update these forward-looking statements.

For more information, visit the Xenogen web site at http://www.xenogen.com

SOURCE: Xenogen Corporation
Onyx Names Scott M. Freeman Vice President, Clinical Development and Helen S. Kim Senior Vice President, Corporate Development
RICHMOND, Calif., March 19 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the appointment of Scott M. Freeman to Vice President, Clinical Development. Dr. Freeman joins the company from Schering-Plough Research Institute where he held the position of Clinical Project Director of Oncology.

``We are very excited to have someone with Scott`s experience and reputation in oncology clinical research join Onyx,`` said Leonard E. Post, Senior Vice President, Research and Development of Onyx. ``Scott brings to us his in-depth experience in oncology clinical development and gene therapy. I am extremely pleased to welcome him to the Onyx management team.``

At Schering-Plough, Dr. Freeman was responsible for the management of several oncology-based clinical programs. Prior to joining Schering-Plough, Dr. Freeman held the positions of Associate Professor and Medical Director of the Blood Center at Tulane University where he managed various programs in research and development of gene therapy for cancer, in addition to managing Tulane`s Blood Center. He also held the position of Adjunct Associate Professor at the University of Rochester and served as a guest researcher at the National Institutes of Health (NIH) from 1986-1990. Dr. Freeman`s career at NIH and academia was distinguished by a fundamental discovery, the bystander effect of prodrug activating gene therapy, and his proposal of one of the first human gene therapy protocols to the NIH Recombinant DNA Advisory Committee. He holds a medical degree from University of Nevada and a Bachelor of Arts degree from University of Colorado.

The company also announced the promotion of Helen S. Kim to Senior Vice President, Corporate Development. Ms. Kim joined Onyx in December 1999 as Vice President, Corporate Development from Protein Design Laboratories, Inc. (PDLI), where she served as Vice President, Marketing and Project Management. Prior to joining PDLI, Ms. Kim was Vice President, Strategic Marketing at Chiron Corporation.

``Helen has been instrumental in guiding Onyx in active corporate development initiatives,`` said Hollings Renton, Chairman and Chief Executive Officer. ``Her contributions will continue to be invaluable as Onyx continues to seek strategic partnerships and build a successful oncology business.``

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the companies collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx and Bayer Present Phase I Study Results of Novel Oral Raf Kinase Inhibitor for Treatment of Cancer
BAY 43-9006 First Orally Active Compound in Class to Undergo Clinical Testing
NEW ORLEANS and RICHMOND, Calif., March 26 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) and its development partner, Bayer Corporation, presented today Phase I clinical results of the companies` novel oral Raf kinase inhibitor, known as BAY 43-9006. The study was presented today at the 92nd Annual Meeting of the American Association for Cancer Research (AACR). The companies also announced results of preclinical studies of BAY 43-9006, which demonstrated the compound`s mechanism of action and its potential applicability in multiple tumor types.

BAY 43-9006 is a selective agent designed to block the Ras signaling pathway in cells by inhibiting a specific enzyme known as Raf kinase. The Ras signaling pathway is believed to play an integral role in the growth of certain cancer tumors, and that blocking this pathway could inhibit tumor growth. Mutations in the Ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and some lung cancers. BAY 43-9006 is the first orally active compound in this class to undergo clinical testing.

``The AACR data suggest that BAY 43-9006 may have activity across a range of tumor types,`` said Hollings Renton, Onyx`s Chairman and Chief Executive Officer. ``Phase I studies in Germany, U.S., Canada and Belgium are ongoing and should be completed later this year. We look forward to moving ahead quickly with further clinical development of this promising compound.``

Wolfgang Plischke, Bayer`s President of the North America Pharmaceutical Division, is encouraged by the research to this point. ``There is an increasing need for new therapy development. By building alliances with the scientific community and industry thought leaders we`re able to accelerate the research of anticancer therapies.``

The goal of the Phase I study was to determine the dose-limiting toxicity, maximum-tolerated dose, pharmacokinetic properties and pharmacodynamic determinants of BAY 43-9006. Twelve patients with refractory solid tumors were treated once every week with single oral doses of BAY 43-9006, ranging from 50 to 400 mg., given at increasing doses. No toxicities have been observed to date.

The companies also presented the results of pre-clinical studies at the AACR meeting demonstrating that BAY 43-9006 inhibits Raf kinase signal transduction. In multiple xenograft tumor models, dose-dependent tumor growth inhibition from 44 to 81 percent was observed. These preclinical data suggest that BAY 43-9006 is an orally available Raf kinase inhibitor with broad antitumor efficacy that suggests the potential for clinical utililty upon further study.

Onyx has collaborated with Bayer since 1994 to discover, develop and commercialize anticancer compounds that inhibit the function or modulate the activity of the Ras pathway. The agreement provides for sharing clinical development costs and resulting profits worldwide except for Japan.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

Bayer Pharmaceuticals is addressing the unmet medical needs of people with cancer by discovering and developing novel therapeutic approaches to the disease. Bayer has initiated Phase I studies in four new anticancer therapies. Already a leader in developing diagnostic techniques for identifying cancers: Bayer is investing $1 billion dollars annually in life-science research.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the companies collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Sangamo BioSciences and Onyx Pharmaceuticals Announce Strategic Alliance To Develop Novel Cancer Therapeutics
RICHMOND, Calif., April 5 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - news) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced that the two companies will jointly research and develop novel cancer therapeutics using Sangamo`s zinc finger DNA-binding protein transcription factor (``ZFP TF``) technology platform and Onyx`s selectively replicating adenovirus technology (``Therapeutic Viruses``). Under the terms of the agreement, the two companies will conduct studies using the combined technology platforms during an investigation period. When product candidates meet certain mutually determined criteria, the companies will equally share research and clinical development costs and jointly commercialize products resulting from the alliance.

ZFP TFs are a class of naturally occurring transcription factors that can be engineered to bind to a precise sequence of DNA to permit the selective regulation of a specific gene. Though there are many kinds of transcription factors, only ZFP TFs are amenable to engineering and capable of targeting a particular gene or genes of interest. Sangamo`s ZFP TF technology can be used to activate or repress virtually any gene.

Onyx is developing a common cold virus (referred to as an adenovirus) that can effectively infect and kill cancer cells leaving normal cells unaffected. Onyx is also testing Therapeutic Viruses capable of delivering a therapeutic payload, such as an engineered ZFP TF, into cells. Under this alliance, Onyx`s Therapeutic Virus will be engineered to deliver a ZFP TF, whose protein product has been shown to augment anti-tumor immune responses, thereby creating an Armed Therapeutic Virus(TM).

``By combining our technologies, we hope to create an Armed Therapeutic Virus(TM) capable of treating the disease both at the tumor site and systemically,`` said Hollings Renton, Onyx`s chairman and chief executive officer. ``The resulting therapeutic will have the potential to be extremely specific, while at the same time allowing treatment of cancer throughout the body after systemic administration of the virus.``

``The ability to provoke an anti-tumor immune response and treat metastatic cancer would be a significant improvement over existing approaches, and together with Onyx, we have the potential to create such a product,`` said Edward Lanphier, Sangamo`s president and chief executive officer. ``This alliance further supports the potential of our ZFP TF technology to be applied in multiple commercially important markets, including its direct use as a human therapeutic.``

About Sangamo

Sangamo is focused on the research and development of novel transcription factors for the regulation of gene expression. Sangamo`s Universal Gene Recognition(TM) technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, human therapeutics, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP transcription factors. In addition, Sangamo is developing novel ZFP-based therapeutics for the treatment of cardiovascular disease. For more information about Sangamo, visit the company`s web site at www.sangamo.com.

About Onyx

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s web site at www.onyx-pharm.com.

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Those forward-looking statements include statements related to the ability of Sangamo BioSciences, Inc. to continue to meet marketing, technology, and customer demands as they relate to its products within the gene regulation market. The development of potential human therapeutic products also involve a number of risks and uncertainties, including but not limited to the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the companies` collaborative relationships. Actual results may differ materially due to a number of factors, including numerous technological, operational and financial challenges associated with the regulation of genes. The matters discussed in this press release also involve risks and uncertainties discussed in the companies` filings with the Securities and Exchange Commission (SEC). In particular, see the risk factors described in these filings including the companies` most recent Annual Reports on Form 10-K and 10-Q. The companies assume no obligation to update the forward-looking information contained in this press release.

SOURCE: Sangamo BioSciences, Inc.
Onyx Names Scott Geyer Vice President, Technical Operations
RICHMOND, Calif., April 9 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the appointment of Scott Geyer to Vice President, Technical Operations. Mr. Geyer joins the company from Protein Design Labs, Inc. (PDLI) where he held the position of Vice President, Technical Development.

``Scott`s expertise in a variety of areas, including manufacturing, process sciences and quality, fits well with one of our key strategic initiatives,`` said Hollings Renton, Chairman and Chief Executive Officer. ``This experience is critical as Onyx matures into a development-oriented company. I am excited to welcome Scott to the Onyx management team.``

Mr. Geyer worked for five years at PDLI in various management positions where he was responsible for all technical development functions. Prior to joining PDLI, Mr. Geyer worked for nine years at the Ares-Serono Group where he held several positions including Executive Director, Process Development. Before that he was a Scientist, Biological Process Sciences at Smith Kline Beckman. He holds a Masters of Science degree in veterinary microbiology from Texas A&M University and a Bachelor of Science degree in microbiology from the University of Southwestern Louisiana.

About Onyx

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
hallo gemeinde,

mich würde mal abgesehen von den US Infos interessieren,
welche meinung ihr über onyx und deren position im krebssektor habt.

danke h.
Onyx Reports First Quarter 2001 Financial Results
RICHMOND, Calif., May 4 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the results of operations for the first quarter ended March 31, 2001.

The company reported a net loss of $5,243,000, or $0.29 per share for the quarter ended March 31, 2001. These results compare with a net loss of $1,680,000, or $0.12 per share for the same quarter in 2000.

Total revenue for the quarter ended March 31, 2001 of $4,736,000 was attributable to amounts earned under the company`s collaborations with Warner-Lambert Company, a subsidiary of Pfizer. Revenue decreased this quarter by $1,101,000 over the same period last year due primarily to the receipt of a payment in the first quarter of 2000 under the inflammation collaboration that was not received this year. Additionally, staffing on the cell cycle collaboration was lower than a year ago resulting in reduced revenue for these efforts.

Total operating expenses for the quarter ended March 31, 2001 of $11,117,000 were $3,205,000 greater than the same period last year. This increase is primarily attributable to the Phase I clinical trials that began in July 2000 with Bayer Corporation and the process development and manufacturing expenses incurred in the first quarter of 2001 under the agreement that was signed with XOMA (US) LLC in January 2001.

As of March 31, 2001, the company had cash, cash equivalents and marketable securities of $77,925,000 compared with $81,994,000 at December 31, 2000. In March 2001, a $5,000,000 equity investment was received from Warner-Lambert.

``Onyx made progress on many fronts during the first quarter,`` said Hollings Renton, Chairman and Chief Executive Officer of Onyx. ``We presented Phase I data at the American Association for Cancer Research meeting on our novel orally active Raf kinase inhibitor, known as BAY 43-9006, that Onyx is co-developing with Bayer. Additionally, we entered into a development and manufacturing relationship with XOMA to increase supply of our lead compound, CI-1042 (ONYX-015), for various clinical trials now underway. We also hired Scott Geyer as Vice President of Technical Operations and Scott Freeman as Vice President of Clinical Research, significantly strengthening our senior management team.``

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.


ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Months Ended
March 31,
2001 2000

Total revenue $4,736 $5,837
Operating expenses:
Research and development 9,385 6,070
General and administrative 1,732 1,842
Total operating expenses 11,117 7,912
Loss from operations (6,381) (2,075)
Interest income, net 1,138 395
Net loss $(5,243) $(1,680)

Net loss per share $(0.29) $(0.12)
Shares used in computing
net loss per share 18,085 13,462


CONDENSED BALANCE SHEETS
(in thousands)

March 31, Dec. 31,
2001 2000
(unaudited) (A)

Assets
Cash, cash equivalents and
marketable securities $77,925 $81,994
Other current assets 5,466 3,083
Total current assets 83,391 85,077
Property and equipment, net 3,067 3,132
Other assets 2,429 388
Total assets $88,887 $88,597

Liabilities and stockholders` equity
Current liabilities $11,574 $10,868
Long-term obligations 708 833
Stockholders` equity 76,605 76,896
Total liabilities and stockholders`
equity $88,887 $88,597


(A)Derived from the audited financial statements included in the Company`s
Annual Report on Form 10-K for the year ended December 31, 2000.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X49622675

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx and Bayer Report Progress With Novel Oral Raf Kinase Inhibitor (BAY 43-9006) for Treatment of Cancer at ASCO Meeting
BAY 43-9006 First Orally Active Compound in Class to Undergo Clinical Testing
SAN FRANCISCO, Calif., May 14 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) and its development partner Bayer Corporation announced that Phase I clinical trial results for their novel oral Raf kinase inhibitor, known as BAY 43-9006, were presented today at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) in San Francisco, California.

The study was designed to determine the compound`s maximum-tolerated dose, toxicity profile, and pharmacokinetic properties when given orally to patients with refractory solid tumors. The presentation reported treatment of 30 patients with single and multiple doses of BAY 43-9006. Toxicities have generally been mild to moderate. Serum levels of BAY 43-9006 observed in preclinical models, which demonstrated antitumor activity, have been achieved in the Phase I dose escalating clinical trial, but dose escalation in this study continues since the companies believe a maximum tolerated dose has not yet been reached.

``We are encouraged by these preliminary data reporting that BAY 43-9006 is well tolerated and has good pharmacokinetic properties,`` said Dirk Strumberg, M.D., West German Cancer Center, who presented the data at the ASCO meeting. ``We look forward to moving ahead with further clinical development of this promising compound to see if it can prevent the progression of a wide variety of cancers.``

Phase I studies in Germany, United States, Canada and Belgium are ongoing. The companies anticipate that they will complete the Phase I studies later this year and, depending on final results of this study, will then initiate Phase II studies.

BAY 43-9006 is a member of the emerging class of therapeutics called selective signal transduction inhibitors of the Ras pathway, and it is the first orally active compound in this class to undergo clinical testing. BAY 43-9006 is a selective agent designed to block the Ras signaling pathway in cells by inhibiting a specific enzyme known as Raf kinase. The Ras signaling pathway is believed to play an integral role in the growth of certain cancer tumors, and blocking this pathway could inhibit tumor growth. Mutations in the Ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and some lung cancers.

Onyx has collaborated with Bayer since 1994 to discover, develop and commercialize anticancer compounds that inhibit the function or modulate the activity of the Ras pathway. The agreement provides for sharing clinical development costs and resulting profits worldwide except for Japan.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s web site at www.onyx-pharm.com.

Bayer Pharmaceuticals is addressing the unmet medical needs of people with cancer by discovering and developing novel therapeutic approaches to the disease. Bayer has initiated clinical studies in four new anticancer therapies. Already a leader in developing diagnostic techniques for identifying cancers: Bayer is investing $1 billion annually in life-science research.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X18729069

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Reports Progress With Its Lead Compound, CI-1042 (Onyx-015), In Phase I/II Clinical Development With Hepatic Artery Infusion in Colorectal Cancer Liver Metastases
SAN FRANCISCO, May 14 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today promising results of a Phase I/II clinical trial with its lead product CI-1042 (ONYX-015) administered via hepatic (liver) artery infusion for the treatment of colorectal cancer liver metastases. The study was presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) in San Francisco, California.

``We are encouraged by these results, which demonstrate that intra-arterial administration of CI-1042 in patients with metastatic colorectal cancer is well tolerated,`` said Hollings Renton, Onyx`s Chairman and Chief Executive Officer. ``This trial provides further evidence that the route of administration of CI-1042 can be expanded beyond direct intratumoral injection, the way CI-1042 is given in the Phase III trial that is currently underway for head and neck cancer. We expect to move forward with clinical development of this promising therapeutic approach in the second half of this year.``

Results of a Phase I/II dose-escalation study of CI-1042 administered by infusion into the hepatic artery to 33 patients with colorectal cancer that had spread to the liver showed this route of administration to be well tolerated. The most common adverse events were mild to moderate fever, rigors and fatigue. CI-1042 was infused into the hepatic artery and subsequent cycles of CI-1042 were administered in combination with intravenous 5-FU and Leucovorin chemotherapy. Objective responses were demonstrated in combination with chemotherapy, including one patient who was refractory to both 5-FU and CI-1042 as single agents. Data also demonstrated that patients treated at the highest dose had prolonged survival compared to the patients treated with the lower dose. The median survival in the low dose arm was 155 days compared to 342 days in the high dose arm. Today, survival has been observed in seven of the patients in the high dose group, while the longest patient has survived for more than two years. These results warrant additional studies.

``Even though the study was not designed nor powered to demonstrate survival differences, we did observe a non-significant trend toward prolonged survival in patients treated with the highest dose of CI-1042,`` said Dr. Tony Reid, Staff Physician at the Stanford University-affiliated Veterans Affairs Palo Alto Health Care System. ``We are encouraged by these study results which demonstrate that CI-1042 can be safely administered via a hepatic artery infusion, and we look forward to its further evaluation in this disease in the next phase of clinical development.``

Colorectal cancer is the third leading cause of cancer death in the United States. Aside from the standard therapies for treatment of colorectal cancer, currently there is no standard treatment specifically for liver metastases of colorectal cancer, other than surgery. Approximately five percent of patients with liver metastases of colorectal cancer have disease that may be surgically treated.

CI-1042 is a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and kill cancer cells that have dysfunctional p53 while sparing normal cells which have wildtype (functioning) p53. p53, a tumor suppressor gene that protects the cell from invaders such as tumors, is the most common genetic abnormality identified in human cancer and is mutated in approximately 50 percent of all human cancers. CI-1042 is being jointly developed by Onyx Pharmaceuticals and Pfizer Inc.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s web site at www.onyx-pharm.com.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X63869930

SOURCE: Onyx Pharmaceuticals, Inc.
kann mir bitte einer in knappen worten auf deutsch übersetzten?danke im voraus.
Onyx Announces Promising Phase II Clinical Results for CI-1042 (Onyx-015) As `Mouthwash` for Premalignant Oral Dysplasia
SAN FRANCISCO, May 15 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today Phase II clinical trial results of its lead product CI-1042 (ONYX-015) for premalignant oral dysplasia that is administered to patients as a mouthwash. The study was presented today at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) in San Francisco, California.

``We are pleased to provide the latest data on CI-1042 -- our novel, selective therapeutic virus product -- that can easily be taken by patients in the form of a mouthwash, suggesting that it may be effective in resolving the premalignant growth,`` said Hollings Renton, Onyx`s Chairman and Chief Executive Officer. ``These results provide further clinical evidence that CI-1042 may be broadly useful in a variety of tumor types.``

The development of oral cavity cancer is frequently preceded by premalignant growths (dysplastic lesions) in the oral mucosa. Researchers presented data demonstrating that CI-1042, given as a mouthwash, is well tolerated and may cause resolution of dysplasia in some patients. CI-1042 was administered at a weekly dose of 1010 particles for 12 weeks. Repeated biopsies were performed to evaluate evidence of persistent disease. Patients demonstrating histologic improvement were eligible to receive another 12 weeks of therapy. In the 10 patients on this regimen, resolution of evident dysplasia was observed in two patients, and improvement in the histologic grade of dysplasia was shown in four patients. Three patients had progression of disease despite therapy, and one patient had initial improvement followed by progression. No significant clinical toxicity has been observed to date.

``The results we have now are preliminary and are based on a small number of patients,`` said Dr. Charlie Rudin, Assistant Professor of Hematology/Oncology Section, Department of Medicine at University of Chicago. ``These results are nevertheless encouraging, demonstrating that CI-1042 can be safely taken as a mouthwash and may selectively eliminate precancerous cells from the oral mucosa of some patients with dysplasia.``

CI-1042 is a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and kill cancer cells that have dysfunctional p53 while sparing normal cells which have wildtype (functioning) p53. p53, a tumor suppressor gene that protects the cell from invaders such as tumors, is the most common genetic abnormality identified in human cancer and is mutated in approximately 50 percent of all human cancers. CI-1042 is being jointly developed by Onyx Pharmaceuticals and Pfizer Inc.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 and Onyx`s pipeline and activities, visit Onyx`s web site at www.onyx-pharm.com.

This press release contains forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports with the Securities and Exchange Commission, including but not limited to its Annual Report in Form 10-K, may affect the actual results achieved by the company.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X33016759

SOURCE: Onyx Pharmaceuticals, Inc.
Future Tech
Mouthwash Might Treat Cancer
Matthew Herper, Forbes.com, 05.18.01, 12:30 PM ET

NEW YORK - Can a mouthwash squash cancer? Maybe, if it`s swarming with tiny viruses that unleash a powerful gene therapy on pre-cancerous cells while leaving healthy tissue alone.

Onyx Pharmaceuticals (nasdaq: ONXX - news - people) presented results of a clinical trial on such a product this week. The "mouthwash" is actually a saline solution filled with the Richmond, Calif., company`s lead product: a virus genetically engineered to attack cells as they become cancerous.

Cells in the mouth turn into cancer tumors only when their genes are heavily damaged, often through heavy use of tobacco or alcohol. This damage doesn`t occur all at once; before tumors appear, lesions show up in the form of red or white patches. The virus should kill these pre-cancerous lesions before they metastasize into cancerous tumors.



Adenovirus gives people colds. Could sloshing a genetically tweaked version in your mouth fight cancer before it happens?


In the recent clinical trial, ten patients who had pre-cancerous lesions in their mouths rinsed with the flavorless solution for half an hour, once weekly for three months. Those that showed improvement were eligible for another three months of treatment. Doctors took biopsies of the tissue to see if it became more or less cancerous.

Two of the ten patients saw patches completely disappear, one for nearly six months. The lesions became less severe in two others and got worse in the rest of the patients. This was a Phase II study, which means it was not aimed at proving conclusively that the treatment works.

The mouthwash was not toxic, although Onyx Senior Vice President of Corporate Development Helen Kim says some patients experienced minor flu-like symptoms, including chills and low fevers. That`s not surprising, given that Onyx`s cancer-fighter is a modified adenovirus, the same bug that causes the common cold.

Swishing with the mouthwash won`t cure cancer after it occurs, because the adenovirus can`t bind to the surface of tumor cells, says David Bouchey, an analyst at New York-based C.E. Unterberg, Towbin. He calls the results promising, although he says much still needs to be proved.

It`s even possible that it`s an immune response that halts the cancer, not the viruses killing cancerous cells. Bouchey doubts an important selling point for the Onyx virus--that it only attacks cells in which a protein called p53 is defective. This defect is common in cancer cells, but not in healthy ones. The company insists that further research has shown the virus does indeed target only cancer cells with defective p53.

Bouchey is bullish on the mouthwash. But he recently lowered his rating on the stock from "neutral" to "avoid" because he thinks the company`s near-term product, an anti-cancer gene therapy that is injected into the body and is being co-developed by drug giant Pfizer (nyse: PFE - news - people), will be too cumbersome for doctors and patients alike.

In 2000, Onyx posted a loss of $7.5 million on revenue of $24.2 million. But it is partnered with deep-pocketed Pfizer and has $82 million in cash and short-term investments that could probably be used to fund further research and clinical trials for some time.
DEAR MISTER PANIK! ES IST JA SCHÖN DAS VIELE INFOS VON ONYX REINSETZT ABER DU KÖNNTEST,AUCH KURZ UND KNAPP INS DEUTSCHE ÜBERSETZEN!!!
Meet the Oncology Experts: An Afternoon With Frank McCormick, Ph.D., F.R.S. And Tony Reid, M.D., Ph.D. to Discuss New Molecular and Biological Approaches
To Treating Cancer in the New Millennium
WHAT: A post-ASCO educational briefing, sponsored by

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news), to discuss new

approaches to treating cancer.


WHO: The meeting will be hosted and led by Frank McCormick, Ph.D.,
F.R.S., Director of the University of California San Francisco
(UCSF) Comprehensive Cancer Center and Cancer Research
Institute. As one of the world`s leading authorities in cancer
research today, Dr. McCormick will provide an overview and
highlight what developments being made today will make the
biggest impact on treatment in the coming decade.

Tony Reid, M.D., Ph.D., Staff Physician at the Stanford
University-affiliated Veterans Affairs Palo Alto Health Care
System will discuss his clinical experience with a promising
new approach to cancer therapy, CI-1042 (ONYX-015), a
tumor-selective, modified adenovirus (similar to the common
cold virus) that has been genetically engineered to replicate
in and kill cancer cells. Dr. Reid will provide a treating
physician`s perspective on how these new types of agents might
affect and alter the way cancer patients are treated in the
future.

WHEN: Tuesday, May 22, 2001 4:30 p.m. - 6:00 p.m. EDT

The post-ASCO briefing will also be available "real-time" over
the Internet; go to www.onyx-pharm.com/framesets/investor.html
and then click on stockholder information; the presentations
will be archived on Onyx`s web site at the above address.

WHERE: The Waldorf=Astoria
West Foyer Room
301 Park Ave.
New York, NY 10022

Contact: Helen Kim, 510-262-8737, ir@onyx-pharm.com
Betsy Rosenberg, 415-221-6044, bprcomm@earthlink.net

SOURCE: Onyx Pharmaceuticals, Inc.
Betrifft Onyx:



Mundspülung mit Viren: eine neue Methode der
Krebstherapie

Mundspülungen mit gentechnisch veränderten
Adenoviren haben sich bei Mundhöhlenkrebs im
Frühstadium als wirksam erwiesen. Über diese neue Art
der Gentherapie berichtete Ezra Cohen von der
University of Chicago auf einer Tagung der American
Society of Clinical Oncology in San Francisco.

Weiße oder rote Flecken der Mundschleimhaut (so genannte
dysplastische Läsionen) sind oft erste Anzeichen von Krebs,
insbesondere bei Rauchern und Alkoholikern. Diese Läsionen
werden meist verursacht von Zellen im Vorkrebsstadium mit
einem Defekt im Tumorsuppressor-Gen p53. Um solche
mutierten Zellen abzutöten, ohne die gesunden Zellen zu
schädigen, können Viren eingesetzt werden. Adenoviren, die
normalerweise Erkältungskrankheiten auslösen, wurden
gentechnisch so verändert, dass sie selektiv nur Zellen mit
defektem p53-Gen befallen und zerstören.

Die therapeutischen Viren werden durch eine Mundspülung mit
den entarteten Zellen in Kontakt gebracht. "Der Vorteil dabei
ist, dass nichts vom Körper absorbiert wird", sagt Cohen. 24
Wochen lang wurden zehn Testpersonen einmal pro Woche so
behandelt. Bei zweien der Patienten waren danach die
Flecken völlig, bei zwei weiteren teilweise verschwunden.

In einer Folgestudie soll die neue Behandlungsmethode nicht
nur bei Krebs im Frühstadium, sondern auch für die
Nachbehandlung von zuvor therapierten Patienten eingesetzt
werden.

nachzulesen unter:

http://www.wissenschaft.de/sixcms/detail.php?id=90214

onxx long!
Mr. Salami
Hallo zusammen!!

Hier Auszüge eines Berichts aus dem
"Global Biotech Investing" von heute:
"Nach der im Biotech-Sektor üblichen
Discount-Cash-Methode ist ONYX PHARMA
derzeit das Dreifache des aktuellen Kurses
wert! So errechnet sich auf der Basis eines
Gewinns von USD 1,67/Aktie im Jahr 2005,
eines KGV´s von 40 und einer Diskontierungsrate
von 35% p.a. ein aktuell angemessener Wert von
USD 27 pro Aktie. Tatsächlich können Sie
ONYX PHARMA aber für USD 10 kaufen! Mit einer
Marktkapitalisierung, die mit aktuell USD 180 Mio.
nur ein Zwanstigstel der Market-Cap. von IMCLONE
beträgt, ist ONYX nur ein Zwerg. Gibt es aber
eine FDA-ZUlassung für Onyx-015 wie von Analysten
erwartet im Jahr 2003 und kann das Marktpotential
von USD 500 Mio. p.a. ausgelotet werden, wird es
im Vorfeld für den Kurs kein Halten mehr geben!"

Klingt doch alles sehr positiv!!
Hoffnungsvoller Gruß von Seinfeld
BusinessWeek Online
INSIDE WALL STREET ONLINE -- Betting on More Biotech Buyouts


INSIDE WALL STREET ONLINE

By Gene Marcial

A significant number of mergers and acquisitions have hit the biotech sector this year. And the betting among industry pros is that more are coming. ``The recent acquisition of Aurora by Vertex, and Celera`s (NYSE:CRA - news) purchase of Axys Pharmaceuticals (AXHP) in mid-June foreshadow a new wave of consolidation in the industry,`` says John McCamanat, editor of the Medical Technology Stock Letter in Berkeley, Calif.
ADVERTISEMENT



The merger wave is partly due to a situation where many companies with exciting technology lack a sound business plan, he says. And biotech executives with solid business acumen who can steer their companies to profitability are in short supply, McCamanat believes. In addition, he says, the cash hordes built up by the larger biotechs will allow several of them to compete with the big pharmaceutical companies for prime acquisitions.

Which are the likely targets? McCamant thinks the activity will revolve around the small and midsize biotechs with market caps below $500 million. Companies that are low on cash are the most vulnerable and will usually consider a merger or acquisition to give them some measure of control over their future. One other factor that will be a key is the syngery in programs and technologies of the two companies planning to combine.

THE ``A`` LIST. Among the stocks that McCamant thinks are vulnerable to being acquired: Hyseq (HYSQ ), which seeks to discover therapeutic targets for its partners using genomics technologies and currently trades at 11.30 a share; Maxim Pharmaceuticals (MAXM ), which develops drugs for cancer and infectious diseases, now at 6.45; NeoRx (NERX ), which develops novel biopharmaceuticals for various cancers, trading at 3.50 a share; Onyx Pharmaceuticals (ONXX ), which makes drugs based on the genetics of human disease, particularly cancer, now at 11.48; Ribozyme (RZYM ), which seeks to identify gene functions, trading at 9.80; StemCells (STEM ), a developer of stem-cell-based drugs to treat diseases of the central nervous system, at 5.39; and Valentis (VLTS ), which produces proprietary gene-delivery systems, trading at 5.92.

Equally good bets for investors, says McCamant, are the large biotechs that are likely to pull the trigger in their acquisition plans. On top of McCamant`s list of would-be acquirers: Chiron (CHIR ), a major biotech focusing on producing biopharmaceuticals, vaccines, and blood-testing products, currently trading at 51; COR Therapeutics (CORR ), which specializes in cardiovascular disorders, currently at 29; Elan (ELN ), a worldwide leader in drug-delivery technology, now at 60; and Cell Genesys (CEGE ), whose gene-modification technology seeks to treat major life-threatening diseases, including prostate cancer, trading at 20.

Chiron tops McCamant`s list for these reasons: Even after acquiring Pathogenesis last year, Chiron is still on the prowl, says McCamant, because it has a need for products in the late stages of clinical trials. And Chiron has funds available that it raised recently specifically for acquisitions.

BETTER FITS. COR also needs new products, and it, too, has sufficient cash, helped by its stock, to make an acquisition. Ditto for Cell Genesys, which also has a good cash position to do a purchase to augment its own drug pipeline. And Elan has a strong history of acquisitions and is known for its ability to make quick and creative decisions. So it could, says McCamanat, announce an acquisition anytime soon.

McCamant says while the big pharmaceutical companies have larger budgets for acquisitions and are very keen on seeking biotech buyouts, he expects many of the deals will be done between the biotech companies, partly because their cultures are more compatible and also because such deals can be more synergistic than they are with the big drugmakers.

The bottom line: McCamant thinks many biotechs are currently undervalued -- and are ripe pickings for a buyout by either the major pharmceuticals or the large biotechs.


Go to www.businessweek.com to see all of our latest stories.
Onyx Pharmaceuticals Reports Second Quarter and Six Months Financial Results
RICHMOND, Calif., Aug. 8 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the results of operations for the second quarter and six months ended June 30, 2001.

The company reported a net loss of $5.9 million, or $0.32 per share for the quarter ended June 30, 2001 compared with net income of $1.4 million, or $0.10 per share for the same quarter in 2000. For the six months ended June 30, 2001, the company reported a net loss of $11.1 million, or $0.61 per share compared with a net loss of $0.2 million, or $0.02 per share for the same period in 2000.

Total revenue was $5.3 million for the quarter ended June 30, 2001 as compared to $9.0 million for the quarter ended June 30, 2000. Total revenue for both quarters was attributable to amounts earned under the company`s research and development collaborations with Warner-Lambert Company, a subsidiary of Pfizer Inc. The major reason for decreased revenue in the current quarter compared to the same quarter in the prior year is that the quarter ended June 30, 2000 included a payment of $3.7 million from Warner-Lambert that was received upon the completion of a research milestone for the armed anticancer virus collaboration.

Total operating expenses of $12.1 million for the quarter ended June 30, 2001 were $4.0 million greater than in the same period last year. This increase is primarily attributable to the Phase I clinical trial that began in July 2000 with Bayer Corporation, for which Onyx pays 50% of the costs, and the process development and manufacturing expenses incurred under the agreement that was signed with XOMA (US) LLC in January 2001.

As a result of the amendment to the 1999 collaboration agreement between Onyx and Warner-Lambert, which was announced today in a separate press release, Onyx assumes responsibility and full ownership of local and regional indications of ONYX-015. Therefore, research and development expenses will increase over current levels, and revenues from Warner-Lambert will stop until trials for intravenous indications are reinitiated.

As of June 30, 2001, the company had cash, cash equivalents and short-term investments of $73.2 million.

``Onyx had a very eventful second quarter,`` said Hollings Renton, Chairman and Chief Executive Officer of Onyx. ``At the 2001 American Society of Clinical Oncology meeting held in San Francisco, we presented promising ONYX-015 data, including the results of a Phase I/II trial in the treatment of metastatic colorectal cancer and also results from a Phase II study in patients with premalignant oral dysplasia. Now that we have full developmental rights to ONYX-015 in local and regional indications, we are excited by the opportunity to bring this promising agent to market as quickly as possible, to the benefit of our stockholders and also the oncology community. Further, with Bayer, we presented Phase I clinical trial results for our novel oral Raf kinase inhibitor, known as BAY 43-9006.``

Thomas Dubensky Promoted to Vice President, Virology

Also, Thomas W. Dubensky, Jr., Ph.D., was promoted to Vice President of Virology after having served as Director of Virus Research since joining Onyx in October 2000. Dr. Dubensky will continue to lead the company`s efforts to discover and develop viruses with systemic efficacy against metastatic disease. Prior to joining Onyx, Dr. Dubensky held the position of Director of Gene Therapy and Vaccines Research at Chiron Corporation.

``Tom`s expertise is an excellent fit with the strategic focus of Onyx,`` said Renton. ``He has already helped us make great strides in our virus research program, and I look forward to his continued leadership in our scientific endeavors.``

Onyx will host a conference call today, Wednesday, August 8, 2001 at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time to discuss the results of the second quarter as well as other business issues. To participate in the conference call, dial 800-498-2168, conference ID #1552657. Or to listen to the webcast of the conference call via the Internet, log on to Onyx`s website at www.onyx-pharm.com 30 minutes prior to the start of the conference, click on the ``What`s New`` tab, read that page and click on the ``LIVE! From InterCall`` icon and follow the instructions.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, ONYX-015. ONYX-015 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications. For more information about ONYX-015 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.


ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2001 2000 2001 2000

Total revenue $5,342 $9,010 $10,078 $14,847
Operating expenses:
Research and development 10,288 6,300 19,673 12,370
General and administrative 1,831 1,818 3,563 3,660
Total operating expenses 12,119 8,118 23,236 16,030
Income (loss) from
operations (6,777) 892 (13,158) (1,183)
Interest income, net 888 546 2,026 941
Net income (loss) $(5,889) $1,438 $(11,132) $(242)
Basic and diluted net
income (loss) per share $(0.32) $0.10 $(0.61) $(0.02)
Shares used in computing
basic net income (loss)
per share 18,434 14,239 18,260 13,852
Shares used in computing
diluted net income (loss)
per share 18,434 14,788 18,260 13,852

CONDENSED BALANCE SHEETS
(in thousands)
June 30, Dec. 31,
2001 2000
(unaudited) (A)
Assets
Cash, cash equivalents and
short-term investments $73,154 $81,994
Other current assets 6,333 3,083
Total current assets 79,487 85,077
Property and equipment, net 3,777 3,132
Other assets 2,290 388
Total assets $85,554 $88,597
Liabilities and stockholders`equity
Current liabilities $13,873 $10,868
Long-term liabilities 583 833
Stockholders` equity 71,098 76,896
Total liabilities and stockholders` equity $85,554 $88,597

(A) Derived from the audited financial statements included in the
Company`s Annual Report on Form 10-K for the year ended December 31, 2000

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx shares fall on changed pact, Q2 results
RICHMOND, Calif., Aug 8 (Reuters) - Shares of Onyx Pharmaceuticals Inc. (NasdaqNM:ONXX - news) fell more than 27 percent in morning trade on Wednesday after the company posted a loss for the second quarter and said it was amending its pact with a unit of Pfizer Inc. (NYSE:PFE - news) on the development of a cancer drug.
ADVERTISEMENT



Onyx shares were down $2.42, or 27.4 percent, to $6.41 on Nasdaq.

Under the amended agreement with Pfizer`s Warner-Lambert Co., Onyx will regain full rights to develop and commercialize the experimental drug ONYX-015 for cancers that are treated with direct injections to tumors, Onyx said.

Warner-Lambert, acquired by Pfizer last year, will retain development rights for ONYX-015 for cancers where the drug is administered intravenously.

Richmond, Calif.-based Onyx said that because of the changes in the pact, its research and development expenses will increase over current levels, and revenues from Warner-Lambert will stop until trials for intravenous indications are re-initiated.

Onyx reported a loss of $5.9 million, or 32 cents per share, for the second quarter, compared with a profit of $1.4 million, or 10 cents per share, a year earlier. Revenues fell to $5.3 million from $9.0 million. Revenues in both periods were from the collaboration pact with Warner-Lambert.

Onyx said revenues decreased primarily because the year-ago quarter included a one-time $3.7 million payment from Warner-Lambert upon completion of a research milestone.
Onyx Names Elizabeth Tillson Vice President, Regulatory Affairs
RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the appointment of Elizabeth Tillson to the newly created position of Vice President, Regulatory Affairs. Ms. Tillson joins the company from Arriva Pharmaceuticals, Inc. where she held the position of Vice President, Regulatory Affairs.

``Elizabeth will oversee all aspects of the company`s regulatory operations, playing an integral role in the advancement of Onyx`s products, including ONYX-015 and our small molecule Raf kinase inhibitor, BAY 43-9006,`` said Hollings Renton, Chairman and Chief Executive Officer of Onyx. ``Elizabeth brings considerable industry experience to Onyx, and her presence will play an important role particularly as we move forward with the clinical development of ONYX-015.``

In her previous position with Arriva Pharmaceuticals, Ms. Tillson was responsible for regulatory affairs, quality assurance and quality control, as well as pre-clinical and clinical studies. Before that, she served as Vice President of Regulatory Affairs at Bachem California, Inc. and as Director of Quality at Chiron Vision Corporation. She came to Chiron Vision from BioSeparations where she was Director of Scientific Affairs. Earlier, at Chiron Corporation, she held positions of increasing responsibility including Associate Director of Regulatory Affairs, Manager of Regulatory Affairs, Project Manager, and Manager of Regulatory Affairs.

Ms. Tillson received her Regulatory Affairs Certification in 1997 and is a Certified Quality Auditor. She received her B.S. and M.S. degrees from the University of Illinois, and earned her Ph.D. in Cell Biology from University of Illinois through its Public Health Service Trainee Fellowship Program.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. For more information about Onyx`s pipeline and activities, visit the Onyx Web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals Reports Third Quarter and Nine Months Financial Results
RICHMOND, Calif., Oct. 30 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the results of operations for the third quarter and nine months ended September 30, 2001.

The company reported a net loss of $6.9 million, or $0.37 per share for the quarter ended September 30, 2001 compared with a net loss of $3.9 million, or $0.27 per share for the same quarter in 2000. For the nine months ended September 30, 2001, the company reported a net loss of $18.1 million, or $0.99 per share compared with a net loss of $4.1 million, or $0.30 per share for the same period in 2000.

Total revenue was $4.5 million for the quarter ended September 30, 2001 as compared to $5.0 million for the quarter ended September 30, 2000. Total revenue for both quarters was attributable to amounts earned under the company`s research and development collaborations with Warner-Lambert Company, a subsidiary of Pfizer Inc. The major reason for decreased revenue in the current quarter compared to the same quarter in the prior year is that, as a result of the amended agreement with Warner-Lambert for the development of ONYX-015 announced in August 2001, Onyx is no longer receiving revenue from Warner-Lambert for this program. As part of that amendment, Onyx assumed responsibility for, and full ownership of, local and regional indications of ONYX-015.

Total operating expenses of $12.1 million for the quarter ended September 30, 2001 were $2.6 million greater than in the same period last year. This increase is primarily attributable to the development costs for ONYX-015, including process development and manufacturing expenses incurred under the agreement that Onyx signed with XOMA (US) LLC in January 2001.

As of September 30, 2001, the company had cash, cash equivalents and short-term investments of $65.4 million.

Onyx also announced today a plan to reduce staff and expenditures while providing the highest priority to products in development. Specifically, Onyx will focus its future spending on: (1) the development of ONYX-015 in order to expedite the product`s time to market; (2) the development of BAY 43-9006 in collaboration with Bayer Corporation; and (3) the selection of the next development product candidate from its novel oncolytic virus platform. In order to manage the quarterly burn rate, Onyx has reduced the size of its workforce by approximately 30% in addition to implementing various cost-saving measures in all areas of the company. The reduction in staffing primarily impacted the research and administrative functions. Onyx will continue to build staff in development functions to ensure the continued development of ONYX-015 and BAY 43-9006. Key hires will continue to be made in clinical development and manufacturing. In research, Onyx will focus on: (a) research and development of the next oncolytic product candidate; (b) the research collaboration with Warner-Lambert on Armed Therapeutic Virus(TM) products; (c) potential collaborative relationships to support the continuation of its research programs to generate novel product candidates from the replicating virus technology platform.

``This decision to reduce our workforce has been a difficult one as many of the employees who have been impacted have made significant contributions to the growth and success of Onyx. However, due to the current unfavorable financing environment, Onyx must be prepared to conserve cash in order to continue to make progress with its late-stage products, ONYX-015 and BAY43-9006,`` said Hollings C. Renton, Chairman of the Board and CEO at Onyx. ``While we are planning to increase our spending to aggressively develop ONYX-015 and BAY 43-9006, our quarterly expenses in 2002 are projected to continue at similar levels as a result of the staffing reductions. We expect that our 2002 quarterly burn rate will increase approximately 50% over the current level, however, due to reduced revenues from Warner-Lambert for development of ONYX-015.``

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. ONYX-015 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications. For more information about ONYX-015 and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.


ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
2001 2000 2001 2000
Total revenue $4,464 $4,995 $14,542 $19,842
Operating expenses:
Research and
development 10,499 7,570 30,172 19,940
General and
administrative 1,601 1,903 5,164 5,563
Total operating
expenses 12,100 9,473 35,336 25,503
Loss from operations (7,636) (4,478) (20,794) (5,661)
Interest income, net 699 574 2,725 1,515
Net loss $(6,937) $(3,904) $(18,069) $(4,146)
Basic and diluted
net loss per share $(0.37) $(0.27) $(0.99) $(0.30)
Shares used in
computing basic
and diluted net
loss per share 18,506 14,399 18,343 14,036


CONDENSED BALANCE SHEETS
(in thousands)
Sept. 30, Dec. 31,
2001 2000
(unaudited) (A)
Assets
Cash, cash equivalents and
short-term investments $65,417 $81,994
Other current assets 5,806 3,083
Total current assets 71,223 85,077
Property and equipment, net 3,975 3,132
Other assets 2,125 388
Total assets $77,323 $88,597
Liabilities and stockholders` equity
Current liabilities $12,675 $10,868
Long-term liabilities 181 833
Stockholders` equity 64,467 76,896
Total liabilities and
stockholders` equity $77,323 $88,597

(A) Derived from the audited financial statements included in the
Company`s Annual Report on Form 10-K for the year ended
December 31, 2000

SOURCE: Onyx Pharmaceuticals, Inc.
Ich bin ja nie ein Freund der Technologie von ONYX gewesen, und habe die Hype um den Wert mit kritischer distanz verfolgt. Aber jetzt kosten die die Hälfte von dem, was sie in den vergangenen 5 Jahren im Schnitt gekostet haben, sie besitzen jetzt wieder die alleinigen Rechte an ihrem Tumorkiller und ihr Marktpreis ist fast auch ihr Cashpreis. Ich verstehe die Leute nicht, die jetzt noch verkaufen (außer aus steuerlichen Gründen).
Nur noch Irre auf dem Parkett.
Ich überlege mir, ob ich mir die nicht auch ins Depot lege, aber s.o.
BAY 43-9006 Phase I Data Presented at 2001 AACR-NCI-EORTC Meeting
RICHMOND, Calif. and WEST HAVEN, Conn., Nov. 1 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) and Bayer Corporation -- Phase I data from clinical trials conducted at the Jules Bordet Institute of Belgium, the Hamilton Regional Cancer Centre and the Princess Margaret Hospital of Canada were presented today for BAY 43-9006, a small molecule Raf kinase inhibitor, at the 12th Annual American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference in Miami, Florida. BAY 43-9006 was codiscovered and is being developed by Onyx and Bayer.

BAY 43-9006 is a member of an emerging class of therapeutics directed toward specific molecular targets misregulated in cancer. BAY 43-9006 selectively blocks signal transduction in the Ras pathway by inhibiting a specific enzyme known as Raf kinase, and is the first orally active compound in this class to undergo clinical testing. The Ras signaling pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway could inhibit tumor growth. Mutations in the ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and 40 percent of lung cancers.

The preliminary data presented today demonstrate the safety, pharmacokinetics and pharmacodynamics of BAY 43-9006 as an anticancer agent in patients with advanced malignancies. In the data presentations, 40 patients with various cancers have been treated in two Phase I clinical trials. BAY 43-9006 has been administered orally at various schedules. Treated patients had advanced cancers including, colorectal, hepatocellular, breast, non-small cell lung, and other cancers. Few adverse events or toxicities clearly related to BAY 43-9006 were reported in the three studies. Patients enrolled in these trials have achieved serum BAY 43-9006 levels equivalent to the levels at which anti-tumor activity was seen in pre-clinical studies. ``In the Canadian study, BAY 43-9006 has been well-tolerated with no consistent grade 3/4 adverse events and no dose limiting toxicities reported up to 100 mg po bid. The study is ongoing and is currently observing 4 patients on 200 mg bid,`` said Dr. Hal Hirte of the Hamilton Regional Centre.

``Presentations on BAY 43-9006 at this meeting provide us with an opportunity to emphasize Onyx`s second product in clinical development,`` said Hollings C. Renton, Chairman of the Board and Chief Executive Officer of Onyx. ``We are pleased that the current preliminary experience with BAY 43-9006 suggests that this agent warrants further study in patients with a wide range of tumor types. Onyx and Bayer anticipate the completion of several Phase I studies in the near term and the initiation of additional clinical trials in the coming months. Bayer has already initiated a Phase I study in patients with acute myelogenous leukemia, as well as in patients with myelodysplastic syndrome. Onyx and Bayer plan to expand this study to a Phase II study after completing the Phase I dose escalation study.``

Onyx has collaborated with Bayer since 1994 to discover, develop and commercialize anticancer compounds that inhibit the function or modulate the activity of the Ras pathway. The agreement provides for sharing clinical development costs and marketing activities worldwide except for Japan. Onyx is developing BAY 43-9006 in partnership with Bayer Corporation.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, ONYX-015. ONYX-015 is currently in a Phase III clinical trial for head and neck cancer. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

Bayer Pharmaceuticals is addressing the unmet medical needs of people with cancer by discovering and developing novel therapeutic approaches to the disease. Bayer has initiated Phase I studies in four new anticancer therapies. Already a leader in developing diagnostic techniques for identifying cancers: Bayer is investing $1 billion annually in life-science research.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.

---------------------------------------------------------





Study Results Highlight Onyx`s Oncolytic Virus Pipeline
RICHMOND, Calif., Nov. 1 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) -- Novel data was presented this week at the 12th Annual American Association for Cancer Research-National Cancer Institute-European Organization for the Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference in Miami, Florida. Researchers presented two abstracts covering Onyx`s next-generation virus research, as well as one abstract which describes novel ONYX-015 clinical data in patients with sarcoma.

``These data add to the growing body of evidence showing that Onyx`s technology platform has significant potential benefits to the oncology community,`` said Leonard Post, Ph.D., Senior Vice President of Research and Development at Onyx.

Data on ONYX-411, a new virus that selectively propagates in tumor cells having a deregulated pRb-signaling pathway, was highlighted in poster presentation today. Extensive pre-clinical studies have shown that ONYX-411 is unable to propagate in normal human cells, yet efficiently kills human tumor cells of diverse origin. Data presented today show that when given intravenously at high doses to mice bearing human tumor xenografts, ONYX-411 demonstrated significant anti-tumor efficacy, without associated toxicity to normal organs.

Further, yesterday, researchers at Onyx presented promising data on its cytosine deaminase (CD) Armed Therapeutic Virus(TM) (ATV) product candidate. CD, an enzyme that converts 5-FC into its highly cytotoxic form, 5-FU, is a commonly used first-line chemotherapeutic agent. ATV is a proprietary technology in which therapeutic genes are placed strategically into Onyx viruses such that expression occurs as a condition of virus replication. Therefore, as replication of Onyx viruses occurs preferentially within cancer cells, expression of the therapeutic transgene is focused within the tumor. In data presented from pre-clinical animal studies, researchers at Onyx showed that CD-ATV provided an enhanced anti-tumor response in the presence of 5-FC, and correlated with high intra-tumoral concentrations of 5-FU, but sub-toxic levels sytemically.

``An extension of the ONYX-015 technology platform designed to increase both the extent and durability of anti-tumor responses, the CD-ATV represents an important next step in the growth of Onyx`s product pipeline,`` added Dr. Post.

Finally, researchers at the Mayo Clinic presented novel ONYX-015 data in chemotherapy-naive patients with sarcoma. In this ongoing dose-escalating Phase I/II study, four patients have been treated to date with ONYX-015 administered via intratumoral injections in combination with a chemotherapy regimen consisting of mitomycin-C, doxorubicin and cisplatin. No serious toxicities related to ONYX-015 have been documented thus far, and ongoing accrual at the highest dose level will allow for a future assessment of efficacy. Sarcomas are tumors of the connective tissues, and approximately 40-75% of sarcomas contain p53 functional mutations. There are approximately 9,800 new cases of sarcoma each year in the United States.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, ONYX-015, which is currently in a Phase III clinical trial for recurrent head and neck cancer. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Im November soll die endgültige Entscheidung über die Zulassung erfolgen. Sollte diese positiv ausfallen, geht onyx durch die Decke. onyx ist übrigens auch seit zwei Wochen im Musterdepot von BörseNow (wohl noch das einzige seriöse Börsenmagazin...)
Onyx Awarded European Patent for Viral Cancer Therapy
RICHMOND, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced that the European Patent Office has granted the company European Patent No. 931830B1, which covers replicating viral-based therapy for treating cancer. The patent specifically covers the use of modified adenoviruses to treat cancer patients having tumors which lack functional retinoblastoma tumor suppressor protein.

``We have filed patent applications throughout the world on this technology, and we were earlier granted a U.S. patent. The addition of these patents to our portfolio, coupled with Onyx`s other patents that cover using another class of modified adenoviruses to treat cancer in patients having tumors which lack a second functional tumor suppressor, p53, gives Onyx a unique and dominant intellectual property position in the field of replicating viruses to treat cancer,`` said Greg Giotta, Vice President and Chief Legal Counsel at Onyx.

``We have published results from human clinical trials of ONYX-015 that demonstrate the proof-of-concept of the therapeutic virus approach,`` said Hollings C. Renton, Chairman of the Board and CEO of Onyx. ``In addition to ONYX-015 which targets tumors with defects in p53 function, Onyx has engineered therapeutic viruses to selectively replicate in and kill cancer cells based on defects in the RB function in these cells. In preclinical studies, we have shown that these viruses produce significant tumor shrinkage in animal models. We have also demonstrated that these therapeutic viruses can be armed with anticancer genes to further enhance tumor-killing power. We intend to make a decision late this year whether one of these viruses will become a clinical development candidate.``

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary virus technologies, the company is developing its lead products, ONYX-015 and BAY43-9006. ONYX-015 is currently in a Phase III clinical trial for head and neck cancer. BAY43-9006 is being developed in collaboration with Bayer Corporation. BAY 43-9006 is currently in Phase I clinical trials in multiple tumor types. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals (ticker: ONXX, exchange: NASDAQ) News Release - 3/5/2002


--------------------------------------------------------------------------------
Onyx and Proacta to Collaborate on Novel Cancer Treatment

RICHMOND, Calif., Mar 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that it has entered into an agreement with Proacta Therapeutics Limited to evaluate and potentially develop a novel cancer treatment. Onyx will provide the therapeutic viruses to Proacta and Proacta will conduct all research activities. Based on the results of the research, the companies may enter into a further collaboration or a license arrangement to develop a nitroreductase (NR) armed virus product.
The companies will investigate arming Onyx therapeutic viruses that replicate in and destroy cancer cells with prodrug technology developed by Proacta. This approach may allow prodrugs to remain inactive in the body until selectively triggered inside a tumor where they kill cancer cells while leaving healthy cells unharmed, potentially enhancing the therapeutic effect of viruses.

"By using the virus as a vector for prodrug technology coupled with the inherent cancer killing power of Onyx`s therapeutic viruses, we believe that there is the potential to produce a highly effective cancer killer that is also safer for patients," said Aki von Roy, Chief Executive Officer of Proacta. "Onyx is a leader in developing oncolytic viruses. Proacta is at the forefront of prodrug technology, so it makes sense for us to work together."

Proacta holds exclusive worldwide rights to 25 patent families. Its technology has shown positive results in quickly destroying cancer tumors in laboratory tests. The agreement with Onyx will allow Proacta to evaluate prodrugs that are activated by the enzyme NR, one of four separate advanced prodrug technology platforms the company has in development. Proacta`s team of scientists is led by Professors Bill Denny and Bill Wilson at the Auckland Cancer Society Research Centre (ACSRC) at the University of Auckland, and by Professor Caroline Springer and Dr Richard Marais at the Institute of Cancer Research in London.

"The collaboration with Proacta will potentially provide Onyx with a second prodrug armed therapeutic virus product. We are currently developing, in collaboration with Pfizer, a therapeutic virus product that is armed with a Cytosine Deaminase (CD) prodrug gene. We believe that armed viruses with anticancer genes, such as prodrug-converting enzymes, will potentially lead to a powerful and yet safe cancer treatment," said Len Post, Senior Vice President of Research and Development at Onyx.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing its lead products, ONYX-015 and BAY 43-9006. For more information about the company`s pipeline and activities, visit Onyx`s website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.
11:25AM Onyx Pharma cancer treatment shows promise-- USA Today (ONXX) 5.30 +0.28: USA Today reports that the co`s live virus ONYX-015 cancer treatment seemed to slow tumor growth safely in 28 patients given high doses in a new study; the high-dose patients survived an average of one year, six months longer than expected.
Onyx Pharmaceuticals (ticker: ONXX, exchange: NASDAQ) News Release - 4/9/2002


--------------------------------------------------------------------------------
BAY 43-9006 Data Presented at 2002 AACR Meeting

RICHMOND, Calif., Apr 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that data supporting the mechanism of action of BAY 43-9006, a small molecule Raf kinase inhibitor, were presented at the annual American Association for Cancer Research Conference in San Francisco, California. BAY 43-9006 was identified as part of a joint research effort between Bayer Corporation and Onyx and is being codeveloped by the companies.
BAY 43-9006 is a novel compound directed toward a specific molecular target misregulated in cancer. Data suggests BAY 43-9006 selectively blocks signal transduction in the Ras pathway by inhibiting a specific enzyme known as Raf kinase, and is the first orally active compound in this class to undergo clinical testing. The Ras signaling pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway may inhibit tumor growth. Mutations in the Ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and 40 percent of lung cancers.

In preclinical studies in vitro, BAY 43-9006 has demonstrated inhibition of Raf-dependent cellular proliferation. In vivo, BAY 43-9006 inhibited tumor growth in several human tumor xenografts. Phase I clinical trials for BAY 43-9006 started in 2000. To date, data have been presented showing results from several single-agent studies.

The data presented today provide biochemical evidence that BAY 43-9006 inhibits the Raf kinase pathway, supporting the mechanistic approach. Evidence of Raf kinase inhibition can be measured by suppression of the level of ERK phosphorylation. The data presented today demonstrated inhibition of ERK phosphorylation in a study of 66 patients treated with BAY 43-9006. Specifically, biomarker studies were conducted with peripheral blood lymphocytes (PBLs) collected from patients with advanced cancers treated with BAY 43-9006 at various dose levels as part of a Phase I clinical trial. PBLs were monitored for BAY 43-9006-dependent inhibition of ERK phosphorylation. Blood samples were collected for analysis before treatment with BAY 43-9006 and on days 1, 2 and 10-21 post treatment to allow comparisons among patients at different dose levels. Investigators reported statistically significant inhibition of stimulated ERK phosphorylation in three out of six patients following continuous treatment with 400 mg bid for 21 days, and in 4 out of 6 patients following continuous treatment with 800 mg bid for 14 days. The time course and extent of ERK inhibition in PBLs was related to the dose level of BAY 43-9006 administered.

Additional data describing the chemistry program leading up to BAY 43-9006 was presented. The investigators presented the optimization process and the molecular structure and activity relationship that led to the novel structure of BAY 43-9006.

"These data provide additional support for the rationale for BAY 43-9006 development. We are extremely encouraged with the biomarker data reported at this meeting. We believe that these data support the mechanism of action of BAY 43-9006 in inhibiting the Raf kinase in the Ras pathway, thereby suppressing the ERK phosphorylation levels. In addition, the data suggest that the dose levels achieved in the Phase I clinical trials are capable of inhibiting the mechanistic target," said Hollings C. Renton, Chairman of the Board and Chief Executive Officer of Onyx. "This important meeting provide us with an opportunity to emphasize BAY 43-9006, Onyx`s second product in clinical development. Onyx and Bayer anticipate the completion of four Phase I studies shortly. In addition, we have an ongoing Phase I/II study in patients with acute myelogenous leukemia and patients with myelodysplastic syndrome. We have recently initiated a Phase I/II study of BAY 43-9006 in combination with a chemotherapy agent. We are currently planning to initiate additional Phase I/II studies of the agent in other chemotherapy combination regimens and Phase II studies of BAY 43-9006 as a single agent in various tumor types."

Onyx has collaborated with Bayer since 1994 to discover, develop and commercialize anticancer compounds that inhibit the function or modulate the activity of the Ras pathway. The co-development collaboration with Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States where the companies can co-promote the product. Everywhere else in the world except Japan, Onyx`s share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds the product and Onyx gets a royalty.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing two lead products, ONYX-015 and BAY 43-9006. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company
ONXX ist auf dem besten Wege, Bollinger bereits klar durch-
brochen, das läßt auf weiter steigende Kurse hoffen.



Hat wohl bis jetzt noch keiner so richtig mitbekommen, daß
hier eine Kursrakete schlummert, dabei ist der Ausbruch
schon im vollen Gange. Das kann allein die Erfolgsmeldung vom
9.April auch nicht bewirkt haben, da scheint mehr dahinter-
zustecken.
Gesten wieder +9%, da ist etwas im Busch, weiß jemand mehr
dazu ?
Bollinger Band nach oben durchbrochen, geht der Trend so
weiter ?

Onyx Reports First Quarter 2002 Financial Results
RICHMOND, Calif., May 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the results of operations for the first quarter ended March 31, 2002.

The company reported a net loss of $9.8 million, or $0.53 per share for the quarter ended March 31, 2002. These results compare with a net loss of $5.2 million, or $0.29 per share for the same quarter in 2001. These results primarily reflect higher clinical development expenditures and lower collaborative revenue as a result of the transfer of certain programs back to Onyx from Warner-Lambert Company, a subsidiary of Pfizer, Inc.

Total revenue for the quarter ended March 31, 2002 of $0.8 million was attributable to research funding for the therapeutic virus collaboration with Warner-Lambert. Revenue is significantly less than the same quarter a year ago, reflecting the amended agreement with Warner-Lambert under which Onyx reassumed control of the clinical development of ONYX-015. In addition, Onyx`s small molecule research collaborations with Warner-Lambert concluded in August 2001, and we are no longer receiving funding for these programs.

Total operating expenses of $11.1 million for the quarter ended March 31, 2002 were flat compared to the same period last year. Onyx indicated that, although its quarterly clinical expenses were approximately $3.3 million more than a year ago, the increase was offset by general and administrative savings that were due to reduced headcount, and reductions to early stage research programs.

As of March 31, 2002, the company had cash, cash equivalents and short-term investments of $48.1 million compared with $58.5 million at December 31, 2001.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing two lead products, ONYX-015 and BAY 43-9006. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.


ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

Three Months Ended
March 31,
2002 2001
(unaudited) (unaudited)


Total revenue $830 $4,736
Operating expenses:
Research and development 9,749 9,385
General and administrative 1,393 1,732
Total operating expenses 11,142 11,117
Loss from operations (10,312) (6,381)
Interest income, net 344 1,138
Other income 175 --
Net loss $(9,793) $(5,243)

Basic and diluted net loss per share $(0.53) $(0.29)
Shares used in computing basic and
diluted net loss per share 18,552 18,085


CONDENSED BALANCE SHEETS
(in thousands)
March 31, Dec. 31,
2002 2001
(unaudited) (A)
Assets
Cash, cash equivalents and
short-term investments $48,126 $58,466
Other current assets 986 900
Total current assets 49,112 59,366
Property and equipment, net 3,337 3,597
Other assets 2,733 2,819
Total assets $55,182 $65,782

Liabilities and stockholders` equity
Current liabilities $9,949 $10,697
Stockholders` equity 45,233 55,085
Total liabilities and
stockholders` equity $55,182 $65,782

(A) Derived from the audited financial statements included in the
Company`s Annual Report on Form 10-K for the year ended
December 31, 2001.

Tell Us What You Think -- Click Here

SOURCE: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals Announces $20 Million Private Placement
RICHMOND, Calif., May 9 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) today announced it raised gross proceeds of $20 million in a private placement. The company sold 2,972,925 shares of its common stock at a price of $6.75 per share. The company also issued warrants to purchase 743,229 shares of its common stock at $9.59 per share. Participants in the financing included Domain Associates, L.L.C., a current shareholder of Onyx, and new investors OrbiMed Advisors, L.L.C., Perceptive Life Sciences Fund, Federated Kaufmann Fund and other investors. Gross proceeds from the offering will be used primarily for working capital purposes, including the clinical development of BAY 43-9006 and ONYX-015. The financing was exempt from registration under the Securities Act of 1933, as amended, pursuant to Regulation D of the Securities Act. The company has agreed to file a registration statement with the Securities and Exchange Commission within 30 days for the resale of the shares. U.S. Bancorp Piper Jaffray served as exclusive placement agent for the equity financing.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing two lead products, BAY 43-9006 and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
New Bay 43-9006 Phase I Data Presented at 2002 ASCO Meeting
WEST HAVEN, Conn. and RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Bayer Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) announced today preliminary Phase I data from clinical trials for a novel anticancer agent. BAY 43-9006, an orally active small molecule Raf kinase inhibitor, was discovered and is being co-developed in a collaboration between Onyx and Bayer. The Phase I data were presented today in a poster by Dirk Strumberg, M.D. of the West German Cancer Center at the University of Essen, at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. An update on safety, pharmacokinetics, pharmacodynamics data and preliminary evidence of antitumor activity was disclosed from the Essen site. Clinical data were also summarized from additional Phase I studies at the Jules Bordet Institute (Belgium), the Hamilton Regional Cancer Centre and Princess Margaret Hospital (Canada), and the Dana Farber Cancer Institute and University of Southern California (US). The data reported two patients with confirmed partial responses and preliminary evidence of tumor shrinkage in five additional patients. In a subset of patients treated at higher doses, 45 other patients also experienced disease stabilization, of which 10 patients had stable disease for six months or longer.

The safety data presented reflects an analysis of 163 patients with various cancers who have been treated in the four Phase I clinical trials where BAY 43-9006 has been administered orally at various schedules at doses up to 800 mg twice daily, as a single agent. The patients in these trials had advanced cancers including colorectal, liver, breast, ovarian, and other cancers whose disease had been previously treated with at least one chemotherapeutic regimen.

The updated results support the previously reported safety data for BAY 43-9006 in patients with advanced malignancies. Toxicities observed in the clinical data presented were generally described as mild-to-moderate by the clinical investigators. The most common dose-limiting toxicities were diarrhea and reversible skin toxicity. There was no myelosuppression seen to date. According to Dr. Strumberg, "Our study was designed to assess the safety, pharmacokinetics and pharmacodynamics of the Raf kinase inhibitor. The clinical trial data presented provide additional support as to the safety profile of this compound in treatment for up to one year."

"In addition to the results from the study conducted in Germany, the Phase I data presented at ASCO includes similar supporting results from clinical studies conducted in Belgium, Canada and the U.S.," added Dr. Susan Kelley, Vice President, Strategic Drug Development at Bayer.

BAY 43-9006 is a novel compound directed toward a specific molecular target misregulated in cancer. Data suggests BAY 43-9006 selectively blocks signal transduction in the Ras pathway by inhibiting a specific enzyme known as Raf kinase, and is the first orally active compound in this class to undergo clinical testing. The Ras signaling pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway may inhibit tumor growth. Mutations in the Ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer and 50 percent of colon cancer.

"These data provide additional support for the rationale for BAY 43-9006 development. We are extremely encouraged by these early clinical data," said Len Post, Senior Vice President, Research and Development at Onyx. "With the Phase I data, we are hopeful that we can move forward to Phase II single-agent studies and studies in combination with standard chemotherapy."

Onyx has collaborated with Bayer since 1994 to discover, develop and commercialize anticancer compounds that inhibit the function or modulate the activity of the Ras pathway. The co-development collaboration with Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States where the companies can co-promote the product. Everywhere in the world except Japan, Onyx` s share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds the product, and Onyx gets a royalty.

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing two lead products, BAY 43-9006 in conjunction with Bayer and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

About Bayer Corporation

Best known for its flagship product, Bayer Aspirin, Bayer Corporation produces a broad range of health care, crop protection, polymer and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability and improve people`s lives.

Headquartered in Pittsburgh, Bayer Corporation had sales of $10.1 billion in 2001 and is one of Fortune magazine`s Most Admired Companies. The company employs 21,500 people. It is a member of the worldwide Bayer Group, a $27 billion international health care and chemicals group based in Leverkusen, Germany. The Bayer Group stock is a component of the DAX and is listed on the New York Stock Exchange (ticker symbol: BAY).

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

SOURCE: Onyx Pharmaceuticals, Inc.
Es ist sehr ruhig geworden um ONXX, ist das die Ruhe vor dem
Sturm ??

.............................................

Wer kann dazu Angaben machen ??

Gruß BOCKNASE
Onyx and Bayer Initiate Phase II Studies of Raf Kinase Inhibitor
Onyx Receives $5 Million Loan Milestone
Wednesday September 4, 6:30 am ET


RICHMOND, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that its partner Bayer Corporation (NYSE: BAY - News) has initiated a single-agent Phase II clinical study of a novel cancer agent, BAY 43-9006, a Raf kinase inhibitor, for the potential treatment of hepatocellular carcinoma. Onyx indicated that initiation of the Phase II program earned a $5 million loan milestone payment for Onyx. The companies advised that additional single-agent Phase II studies are planned. Bayer said separately that a Phase II study in colorectal cancer is expected to begin this quarter.
ADVERTISEMENT


The preliminary findings of four Phase I studies -- in Canada, the U.S., Belgium and Germany -- provided rationale for undertaking the Phase II study. Preliminary data from Phase I studies were reported at both the American Association for Cancer Research and the American Society of Clinical Oncology meetings earlier this year. Those data were used to determine the safety profile of the small molecule compound. Also presented were data that included two patients with confirmed partial responses; preliminary evidence of tumor shrinkage in five additional patients; and, in a subset of patients treated at higher doses, 45 patients who had disease stabilization. "Since this molecule targets the Ras pathway -- a pathway that data suggest plays a role in cell proliferation -- we are looking forward to the commencement of Phase II studies," commented Chairman and Chief Executive Officer of Onyx, Hollings C. Renton.

In addition to exploring the utility of BAY 43-9006 alone in the hepatocellular Phase II trial, Bayer and Onyx have planned clinical trials in combination with a range of standard chemotherapeutics. Initially, these studies aim to identify regimens of the combined therapy that are sufficiently well tolerated. That would set the stage for follow-up Phase II and III studies to demonstrate the safety and efficacy profiles of the therapy.

BAY 43-9006, an orally active small molecule Raf kinase inhibitor, was discovered and is being co-developed in a collaboration between Onyx and Bayer. Data suggest that BAY 43-9006 selectively blocks signal transduction in the Ras pathway by inhibiting a specific enzyme known as Raf kinase, and is the first orally active compound in this class to undergo clinical testing. The Ras signaling pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway has been shown to inhibit tumor growth in vivo. Mutations in the Ras gene occur in approximately 30 percent of all human cancers, including 90 percent of pancreatic cancer and 50 percent of colon cancer.

The co-development collaboration with Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States where the companies can co-promote the product. Everywhere in the world except Japan, Onyx`s share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds the product, and Onyx gets a royalty.

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing two lead products: BAY 43-9006 in conjunction with Bayer, and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

About Bayer Corporation

Best known for its flagship product, Bayer Aspirin, Bayer Corporation produces a broad range of healthcare, crop protection, polymer and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability and improve people`s lives.

Headquartered in Pittsburgh, Bayer Corporation had sales of $10.1 billion in 2001 and is one of Fortune magazine`s Most Admired Companies. The company employs 21,500 people. It is a member of the worldwide Bayer Group, a $27 billion international healthcare and chemicals group based in Leverkusen, Germany. The Bayer Group stock is a component of the DAX and is listed on the New York Stock Exchange (ticker symbol: BAY).

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture its products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Onyx Regains All Rights to Virus Platform and Initiates Repartnering Efforts
Monday September 16, 4:27 pm ET


RICHMOND, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that it has regained full rights to ONYX-015 having ended its agreement with Warner-Lambert Company, a subsidiary of Pfizer Inc. (Nasdaq: PFE - News) since June 2000. The company said it has also regained rights to an Armed Therapeutic Virus(TM) product formerly partnered with Pfizer.
ADVERTISEMENT


"By regaining full rights to these products, we now can offer a potential partner a pipeline of late-stage clinical and preclinical product candidates. We are confident that we can move forward with a partner willing to participate in a broad development program," explained Chairman and Chief Executive Officer Hollings C. Renton.

The collaboration between Onyx and Warner-Lambert began in September 1999 and was amended in August 2001. Even though Warner-Lambert reserved certain rights to ONYX-015 intravenous administration, Onyx had assumed all financial and development responsibility for the product. The amendment announced today returns Warner-Lambert`s remaining rights without significantly affecting Onyx` development expenses and without any future financial obligations to Warner-Lambert. Warner-Lambert`s research funding ends in the third quarter.

The lead virus product, ONYX-015, is currently being evaluated in two trials for the treatment of squamous cell carcinoma of the head and neck, one in recurrent and one in refractory disease. Results of earlier Phase II studies showed the drug was well tolerated with encouraging signs of therapeutic activity in head and neck cancer. In addition, early signs of activity were demonstrated in a Phase I/II study in patients with metastatic colorectal cancer.

ONYX-015 is a tumor-selective, modified adenovirus that has been genetically engineered to replicate in and kill cancer cells that have an abnormal p53 pathway while sparing normal cells that have a functioning p53 protein. p53, a protein that protects the cell from developing into a cancer cell, is the most commonly altered gene in human cancer.

Onyx also has an adenovirus that selectively replicates in and kills cancer cells based on genetic defects in the retinoblastoma (RB) tumor suppressor gene. This product, being developed independently by Onyx, is known as ONYX-411. ONYX-411 has been shown to have potent and selective killing in a broad range of tumors and has demonstrated antitumor activity in animal models following intravenous administration.

Onyx has evidence that the selectivity and amplification features of ONYX- 015 and ONYX-411 can be used in the delivery of therapeutic genes to tumor cells. Onyx scientists have developed a proprietary process for insertion of genes into the viruses to create Armed Therapeutic Virus(TM) products.

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing two lead products, BAY 43-9006 in conjunction with Bayer and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals Reports Third Quarter and Nine Months Financial Results
Thursday November 14, 4:00 pm ET


RICHMOND, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) announced today the results of operations for the third quarter and nine months ended September 30, 2002.
ADVERTISEMENT


The company reported a net loss of $10.8 million, or $0.50 per share for the quarter ended September 30, 2002 compared with a net loss of $6.9 million, or $0.37 per share for the same quarter in 2001. For the nine months ended September 30, 2002, the company reported a net loss of $32.5 million, or $1.61 per share compared with a net loss of $18.1 million, or $0.99 per share for the same period in 2001. The results for the current quarter are consistent with the first two quarters of 2002.

The results for the current quarter and nine months ended September 30, 2002 reflect higher clinical development and manufacturing expenditures and lower collaborative revenue as a result of the transfer of ONYX-015 financial and development responsibility back to Onyx from Warner-Lambert Company, a subsidiary of Pfizer, Inc, previously announced in August 2001. In addition, during the nine months ended September 30, 2002, clinical development expenses have increased over the same period in the prior year for BAY 43-9006, the orally active small molecule raf kinase inhibitor that is being developed in a collaboration between Onyx and Bayer Corporation. With respect to BAY 43-9006, multiple Phase I clinical trials are currently in progress, and the first Phase II clinical trial was initiated in the quarter ended September 30, 2002.

Total revenue was $1.2 million for the quarter ended September 30, 2002 as compared to $4.5 million for the quarter ended September 30, 2001. Revenue for the quarter ended September 30, 2002 was attributable to research funding for the therapeutic virus collaboration with Warner-Lambert. Based on the termination of the collaboration agreement announced in September 2002, no further revenue will be received from Warner-Lambert. The revenue decline from the same quarter a year ago reflects the amendment of agreements with Warner-Lambert last year, as previously announced.

As of September 30, 2002, the company had cash, cash equivalents and short-term investments of $50.4 million. In August 2002, the company received a $5 million milestone-based loan payment from Bayer for the initiation of the BAY 43-9006 Phase II clinical program.

The company will webcast a conference call today at 4:45 p.m. EST to discuss the third quarter financial results and current development activities. Hollings C. Renton, chairman and chief executive officer, will host the call. To access the webcast, log on to www.onyx-pharm.com, click on the "Investor Relations" tab, and click on "Webcast-November 14, 2002". The webcast may also be accessed directly through PRNewswire/First Call by going to http://www.firstcallevents.com/service/ajwz369995019gf12.html . Please log on 15 minutes in advance to determine software requirements for accessing the webcast. A replay of the webcast will be available through both the Onyx and the PRNewswire/First Call websites two hours after the completion of the call through November 28, 2002.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing two lead products, BAY 43-9006 and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001

Total revenue $1,178 $4,464 $2,715 $14,542
Operating expenses:
Research and development 10,921 10,499 32,027 30,172
General and administrative 1,407 1,601 4,349 5,164
Total operating expenses 12,328 12,100 36,376 35,336
Loss from operations (11,150) (7,636) (33,661) (20,794)
Interest income, net 272 699 936 2,725
Other income 60 -- 235 --
Net loss $(10,818) $(6,937) $(32,490) $(18,069)
Basic and diluted net loss
per share $(0.50) $(0.37) $(1.61) $(0.99)
Shares used in computing
basic and diluted net
loss per share 21,593 18,506 20,178 18,343


CONDENSED BALANCE SHEETS
(in thousands)

Sept. 30, Dec. 31,
2002 2001
(unaudited) (A)
Assets
Cash, cash equivalents and
short-term investments $50,381 $58,466
Other current assets 1,571 900
Total current assets 51,952 59,366
Property and equipment, net 3,203 3,597
Other assets 2,443 2,819
Total assets $57,598 $65,782
Liabilities and stockholders` equity
Current liabilities $10,729 $10,697
Long-term debt 5,000 --
Stockholders` equity 41,869 55,085
Total liabilities and stockholders` equity $57,598 $65,782


(A) Derived from the audited financial statements included in the Company`s Annual Report on Form 10-K for the year ended December 31, 2001.
Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Onyx Provides Update of Development Programs; Meets Key Manufacturing Milestone
Thursday November 14, 4:02 pm ET


RICHMOND, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals Inc. (Nasdaq: ONXX - News) today announced that BAY 43-9006, a novel anticancer investigational agent, is moving toward potential Phase III clinical trials in 2003. BAY 43-9006 is an orally active small molecule raf kinase inhibitor being developed in collaboration with Bayer Corporation. Onyx also reported that the U.S. Food and Drug Administration (FDA) has approved an amendment Onyx filed to the Chemistry, Manufacturing and Controls (CMC) section of its Investigational New Drug (IND) application for ONYX-015, allowing the company to use product manufactured at XOMA (US) LLC at a larger scale. At the same time, the company reiterated that it is actively seeking a partner for its therapeutic virus program -- including the lead product candidate in this program, ONYX-015 -- in order to reduce its burn rate.
ADVERTISEMENT


Clinical Progress of BAY 43-9006

"Bayer and Onyx plan to begin Phase III clinical studies of BAY 43-9006 during 2003, after the Phase III strategy is finalized and plans are reviewed with and approved by relevant health authorities," said Hollings C. Renton, Onyx chairman and chief executive officer.

Preliminary Phase I clinical data for BAY 43-9006 were reported at the 2002 annual meeting of the American Society of Clinical Oncology (ASCO) and will be updated in Frankfurt, Germany at EORTC-NCI-AACR 2002 (European Organization for Research and Treatment of Cancer -- National Cancer Institute -- American Association for Cancer Research 2002 meeting) on November 20.

These encouraging early data supported the initiation of the first Phase II efficacy study of BAY 43-9006 as a single agent during the third quarter, triggering a $5 million milestone-based loan payment to Onyx. Multiple Phase I clinical trials of this novel agent in combination with a range of chemotherapeutics are also ongoing. Data from these studies will be presented at upcoming scientific meetings, and will be used to guide decisions to advance BAY 43-9006 toward approval. Upon the commencement of Phase III studies, Onyx will receive $15 million in loan funding from Bayer.

BAY 43-9006 is an inhibitor of the enzyme raf kinase, a critical component of the ras pathway -- a cascade of chemical signals that control cell division. Abnormal activation of the ras pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway may inhibit tumor growth. Mutations in the ras gene occur in approximately 30 percent of all human cancers, including 80 percent of pancreatic cancer, 50 percent of colon cancer and 30 percent of non-small cell lung cancer, according to the American Cancer Society.

Development Update on ONYX-015

The clinical progress of ONYX-015 has been limited to date by the supply of material. Working with XOMA, Onyx has been able to scale up the manufacturing process by tenfold. The FDA`s approval of the CMC amendment allows the use of material made at this larger scale and significantly reduces the supply constraints for clinical development.

Onyx is taking steps to position its therapeutic virus program for new partnering opportunities. In September, Onyx cleared the path to re-partner this program when it reacquired all rights to ONYX-015 and an Armed Therapeutic Virus(TM) product from Warner-Lambert Company, a subsidiary of Pfizer, Inc.

Onyx is conducting a Phase II trial of ONYX-015 in refractory head and neck cancer. Early results from this trial may be useful in the ongoing dialog with the FDA about potential registration in head and neck cancer. Although a Phase III trial remains open in recurrent head and neck cancer, the company is not actively recruiting patients until agreement is reached with the FDA regarding the registration path.

Onyx is planning a clinical trial of ONYX-015 in metastatic colorectal cancer to establish a safe dose in combination with standard chemotherapeutic regimens. Data from an earlier Onyx Phase I/II study showed early signs of activity in this indication. Patients receiving the highest dose experienced extended survival compared with patients receiving lower doses. Signs of tumor shrinkage were observed in a few patients that had failed several regimens of chemotherapy. There are more than 150,000 newly diagnosed patients with colorectal cancer annually in the U.S., and approximately 30 percent of those patients will develop metastatic disease.

"We are actively seeking a partner for our therapeutic virus program to reduce our burn rate," said Mr. Renton. "With this approved new supply source for ONYX-015, an additional registration path in metastatic colorectal cancer, and follow-on candidates, we believe we have an attractive package to offer a partner."

Webcast of Conference Call

Onyx announced that it will webcast a conference call today, November 14, 2002, at 4:45 p.m. EST to discuss the third quarter financial results and current development activities. Hollings C. Renton, chairman and chief executive officer will host the call. To access the webcast, log on to www.onyx-pharm.com, click on the "Investor Relations" tab, and click on "Webcast -- November 14, 2002." The webcast may also be accessed directly through PR Newswire/First Call by going to http://www.firstcallevents.com/service/ajwz369995019gf12.html . Please log on 15 minutes in advance of the call to determine software requirements for accessing the webcast. A replay of the webcast will be available through both the Onyx and the PRNewswire/First Call websites two hours after the completion of the call through November 28, 2002.

New Website Launched

Onyx also announced that it will relaunch its website, www.onyx-pharm.com, on Friday, November 15, 2002. The site has been redesigned to provide investors, patients and the medical community with an updated and comprehensive view of the company, its clinical candidates and product development programs.

About Onyx

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. Based on its proprietary technologies that target the molecular basis of cancer, the company is developing two lead products, BAY 43-9006 and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s newly updated website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture our products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Onyx Updates Phase I Data for BAY 43-9006 at 2002 EORTC-NCI-AACR Meeting in Frankfurt
Wednesday November 20, 6:00 am ET


RICHMOND, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced updated Phase I clinical data for BAY 43-9006, a novel anticancer investigational agent. BAY 43-9006 is an orally active small molecule raf kinase inhibitor being co-developed in a collaboration between Onyx and Bayer. The updated data were presented today in Frankfurt, Germany, at the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) 2002 meeting.
ADVERTISEMENT


Safety and preliminary signs of antitumor activity were presented in posters from three of four clinical sites, including: the West German Cancer Center at the University of Essen, the Jules Bordet Institute in Belgium, and the Hamilton Regional Cancer Centre and Princess Margaret Hospital in Canada. An additional summary table included patients from a Phase I trial at the Dana Farber Cancer Institute and the University of Southern California in the United States.

To date, a total of 27 of 114 patients treated at higher doses remain on BAY 43-9006 with disease that had not progressed after more than six months, and seven patients have been treated with BAY 43-9006 for more than one year, also with no disease progression. Of these, a patient with a previously reported partial response with hepatocellular carcinoma has remained on BAY 43-9006 therapy without progression over nine months, and a second patient with a partial response with renal cell carcinoma was on study for 44 weeks before progressing.

In these trials, BAY 43-9006 was administered orally at various schedules at doses up to 800 mg twice daily, as a single agent, to patients with advanced cancers, including colorectal, liver, breast, ovarian, and other cancers whose disease had been previously treated with at least one chemotherapeutic agent. The updated results support the previously reported safety data for BAY 43-9006 in patients with advanced malignancies.

Toxicities described in the clinical data presented were generally described as mild-to-moderate by the clinical investigators. The most common dose-limiting side effects were diarrhea and reversible skin toxicity. There was no myelosuppression seen to date. Based on these studies, a Phase II dose was determined to be 400 mg twice a day continuous treatment.

Data reported from the Belgium poster reports a subset of five patients with renal cell carcinoma treated for an average of more than 23 weeks, in which one had a partial response and four demonstrated stable disease. In addition, three patients including the partial response, experienced tumor shrinkage of greater than 20 percent.

"Our early data in a small sample of ovarian cancer patients showed that three of five patients treated with BAY 43-9006 achieved stable disease, and two of these patients continue to be treated after one year," stated Dr. Hal Hirte of the Hamilton Regional Cancer Center in Canada.

"These Phase I clinical data provide additional support pointing to the potential tolerability of this raf kinase inhibitor, which is important information as we plan our Phase III program," said Leonard E. Post, Ph.D., Onyx senior vice president, research and development.

About BAY 43-9006

BAY 43-9006 is a novel investigational compound directed against a specific molecular target misregulated in cancer. Data suggest BAY 43-9006 may selectively block signal transduction in the ras pathway by inhibiting a specific enzyme known as raf kinase. It is the first orally active compound in this class to undergo clinical testing. Abnormal activation of the ras pathway is believed to play an integral role in the genesis of many cancers, and blocking this pathway may inhibit tumor growth. Mutations in the ras gene occur in approximately 30 percent of all human cancers, including 80 percent of pancreatic cancer, 50 percent of colon cancer and 30 percent of non-small cell cancer, according to the American Cancer Society.

The co-development collaboration between Onyx and Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States, where the companies can co-promote the product. Everywhere else in the world except Japan, Onyx`s share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds product development, and Onyx receives a royalty.

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing two lead products: BAY 43-9006 in conjunction with Bayer, and ONYX-015. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture its products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Investors Take a Shine to Onyx

By Adam Feuerstein
Senior Writer
11/21/2002 01:53 PM EST
Click here for more stories by Adam Feuerstein


Investors in search of the next hot cancer drug prospect are once again taking notice of Onyx Pharmaceuticals (ONXX:Nasdaq - news - commentary - research - analysis).

Shares of the tiny Richmond, Calif.-based biotech firm have shot up 32% in the past two days on a new dose of encouraging, though early, clinical data for its novel cancer-fighting compound, which is known as BAY 43-9006. Onyx shares were up 12% to $6.06 Thursday.


Onyx presented positive updated results from a phase I trial of BAY 43-9006 given to patients with several types of advanced solid tumors. Normally, such early data wouldn`t elicit much of a response, but the company said last week that along with partner Bayer (BAY:NYSE - news - commentary - research - analysis) it plans to start final, phase III studies next year.

"I don`t think Bayer would let Onyx move this drug quickly into phase III testing unless their confidence was high," says John McCamant, editor of the Medical Technology Stock Letter. At these prices, Onyx is a recommended stock in McCamant`s model biotech portfolio.

Deja Vu
In many ways, this week`s run-up in Onyx shares mimics a similar, though short-lived, move last spring. At that time, the stock doubled to more than $8 after positive preliminary phase I data on BAY 43-9006 was presented at the closely watched American Society of Clinical Oncology annual meeting. But Onyx shares slipped back into the low single digits in the summer as the market slid to its lows.

In a recent research note, A.G. Edwards biotech analysts Craig West and Alex Hittle said the decision by Onyx to move BAY 43-9006 quickly into phase III testing was a positive, although surprising, move given that most drug companies hold back until early and midstage studies are completed. But again, the analysts say Onyx`s low valuation provides counterbalance to the added risk. They have a buy rating and a 12-month to 18-month price target of $10 on Onyx. Their firm doesn`t have a banking relationship with the company.
Onyx Presents Data on Tumor-Specific Intravenous Gene Delivery at 11th International Conference on Gene Therapy of Cancer
Friday December 13, 5:30 pm ET


RICHMOND, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced the presentation of preclinical data showing the ability of ONYX-411, a second-generation therapeutic virus, to specifically deliver anticancer gene products to tumors following systemic (intravenous) administration. The presentation was given today by Yuqiao Shen, Ph.D., senior scientist of Onyx Pharmaceuticals at the 11th International Conference on Gene Therapy of Cancer in San Diego, California.
ADVERTISEMENT


"We believe these results provide compelling in vivo evidence that ONYX-411, an adenovirus engineered to selectively replicate in tumors with mutations in the retinoblastoma (RB) pathway, can be used as a safe and efficient vector for the delivery of gene products to the tumor," said Leonard Post, Ph.D., Onyx senior vice president, research and development. "Onyx` proprietary technology for inserting the therapeutic gene into the vector is designed to ensure that the gene is expressed only when the virus replicates. Since the virus is designed to replicate only in tumors, the gene expression is restricted to the tumors. Using this technology, we believe we can increase the cancer-killing properties of our viruses while minimizing the effect on healthy cells, even after intravenous administration."

In his presentation, Dr. Shen described experiments in which ONYX-443 was administered intravenously to immunodeficient mice carrying human tumor xenografts. ONYX-443 is an Armed Therapeutic VirusTM product constructed by modifying ONYX-411 to express a gene that makes the enzyme cytosine deaminase (CD). CD converts a non-toxic prodrug (5-fluorocytosine, or 5-FC) into a highly toxic chemotherapeutic agent (5-fluorouracil, or 5-FU). Dr. Shen reported that strong expression of CD was detected only in tumors, not in liver or other normal tissues, following the systemic administration of ONYX-443. Moreover, during time course studies (five days post-virus injection until 24 days post-injection in some experiments), CD expression in tumors increased with time, presumably due to the continuous replication and spread of the virus. Expression of CD appeared to correlate with virus replication in vivo.

"We believe this technology opens up the possibility for intravenous delivery of cancer gene therapy, an important development since it will allow treatment of metastatic disease beyond the tumors that can be targeted by local administration," added Dr. Post.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing two lead products: BAY 43-9006 in conjunction with Bayer, and ONYX-015. For more information about Onyx` pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture its products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Onyx steigt in den letzten Tagen ohne erkennbaren Grund.



Kann sich dazu jemand mit Erkenntnissen äußern ?

MfG Bocknase
Onyx Reports Fourth Quarter and Year-End 2002 Financial Results
Thursday February 27, 4:30 pm ET


RICHMOND, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) reported a net loss of $13.3 million, or $0.62 per share for the fourth quarter ended December 31, 2002 compared with a net loss of $9.5 million, or $0.51 per share for the same quarter in 2001. For the year ended December 31, 2002, the company reported a net loss of $45.8 million, or $2.23 per share, compared with a net loss of $27.6 million, or $1.50 per share, for the same period in 2001.
ADVERTISEMENT


The results for the quarter and year ended December 31, 2002 reflect higher clinical development expenditures for Onyx`s lead product, BAY 43-9006, an orally active small molecule raf kinase inhibitor that is being developed in a collaboration between Onyx and Bayer Corporation. In addition, as a result of the August 2001 reacquisition of rights to ONYX-015 and an Armed Therapeutic Virus(TM) product from Warner-Lambert Company, a subsidiary of Pfizer, Inc, and the September 2002 termination of the companies` collaborative agreement, Onyx recorded higher manufacturing and clinical expenses as well as lower collaborative revenue in the fourth quarter and year ended December 31, 2002 than in the corresponding periods in the prior fiscal year.

In January 2003, the company announced that it restructured its operations to reflect an increased priority on the development of BAY 43-9006. Onyx suspended the development of ONYX-015, including clinical trials and manufacturing activities, pending ongoing partnering discussions, and reduced staff levels by 25%. As a result, the company announced that for 2003, it projected quarterly operating expenses in the $9.0 million range, excluding certain restructuring and other one-time charges.

As of December 31, 2002, the company had cash, cash equivalents and marketable securities of $39.8 million. Earlier this month, the company announced that it raised $10.0 million in a private placement of common stock primarily with Deerfield Management Company, Inc.

For the quarter ended December 31, 2002, Onyx reported no revenue as compared with total revenue of $1.3 million for the same quarter a year ago. The revenue reflected research funding received from Warner-Lambert for the now-terminated therapeutic virus collaboration.

Total operating expenses for the quarters ended December 31, 2002 and 2001 were $13.4 million and $12.1 million, respectively. The fourth quarter 2002 results include a $2.5 million increase in expenses versus the same quarter in the prior year related to the co-development of BAY 43-9006, specifically multiple, ongoing Phase I clinical trials and Phase II clinical trials initiated in September 2002. The fourth quarter 2002 results did not include restructuring costs as compared with the same period in the prior year where the company recorded expenses of $0.8 million related to a December 2001 reduction in force.

For the years ended December 31, 2002 and 2001, total revenue was $2.7 million and $15.8 million, respectively, primarily representing research and development funding from the now-discontinued Warner-Lambert collaboration. The decrease in revenue in 2002 is a result of the August 2001 conclusion of ONYX-015 development cost reimbursement and small molecule research collaborations with Warner-Lambert. In addition, following the termination of the therapeutic virus research collaboration with Warner-Lambert in September 2002, no further funding was received for this program.

Total operating expenses in 2002 of $49.8 million were $2.4 million greater than in 2001. Expenses related to the co-development and clinical trial costs of BAY 43-9006 with Bayer increased by $6.3 million. Development costs for ONYX-015 increased by $6.2 million. The increased expenses for these programs were partially offset by a decrease of $10.1 million in expenses for therapeutic virus and small molecule research programs, due to the company`s December 2001 restructuring of research functions and corresponding reduction in force.

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 in co-development with Bayer. In addition, the company`s preclinical portfolio includes proprietary therapeutic viruses and Armed Therapeutic Virus(TM) products. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This press release contains certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, dependency on third parties to manufacture its products, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company.

ONYX PHARMACEUTICALS, INC.
SUMMARY FINANCIAL INFORMATION

STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

Three Months Ended Year Ended
December 31, December 31,
2002 2001 2002 2001
(unaudited) (unaudited) (unaudited) (A)

Total revenue $-- $1,304 $2,715 $15,846
Operating expenses:
Research and development 11,765 9,755 43,792 39,927
General and administrative 1,655 1,488 6,004 6,652
Restructuring and other -- 812 -- 812
Total operating
expenses 13,420 12,055 49,796 47,391
Loss from operations (13,420) (10,751) (47,081) (31,545)
Interest income, net 223 498 1,159 3,223
Other income (expense) (100) 750 135 750
Net loss $(13,297) $ (9,503) $ (45,787) $ (27,572)
Basic and diluted net
loss per share $(0.62) $(0.51) $(2.23) $(1.50)
Shares used in computing
basic and diluted net
loss per share 21,595 18,510 20,535 18,385


CONDENSED BALANCE SHEETS
(in thousands)

Dec. 31, Dec. 31,
2002 2001
(unaudited) (A)
Assets
Cash, cash equivalents and
marketable securities $39,833 $58,466
Other current assets 1,351 900
Total current assets 41,184 59,366
Property and equipment, net 2,834 3,597
Other assets 2,223 2,819
Total assets $46,241 $65,782

Liabilities and stockholders` equity
Current liabilities $12,457 $10,697
Advance from partner 5,000 --
Stockholders` equity 28,784 55,085
Total liabilities and
stockholders` equity $46,241 $65,782

(A) Derived from the audited financial statements included in the
Company`s Annual Report on Form 10-K for the year ended December 31,
2001.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Überwindung des Widerstandes bei 8,40 fraglich ????????

Wahrscheinlicher Rücksetzer auf 7,20

Meine Meinung, da total überverkauft

JS200
ONXX
ONYX PHARMACEUTICALS INC
8.460
+0.260 +3.17%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/14/2003 (5) days ago, when the stock price was 7.850. Since then the stock gained 7.77% .

Today the stock closed higher with a higher high and a lower low (sign of increase in volatility). The volume is extremely high. The security price is trending up and is overbought.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Long White Candlestick


Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!





Stock Quote
Last 8.460
Previous Close 8.200
Change +0.260
% Change +3.17%
Volume 170,165
Stock Activity
Open 8.200
Day`s High 8.660
Day`s Low 7.750
52 Week High 8.460
52 Week Low 3.590


Stock Price History
3 Month % Change 38.92
6 Month % Change 105.34
12 Month % Change 78.11
Stock Statistics
50 Day Close MA 6.197
200 Day Close MA 5.252
65 Day Volume MA 81,465

JS200
03/20/2003 (07:02 ET) CONF: ONXX To Present At SG Cowen Health Care Conference @ 09:00 ET - Knobias
03/10/2003 (06:12 ET) Research and Markets: Onyx Pharmaceuticals Inc.(ONXX) - Quantitative Valuation Report - M2 Communications
03/07/2003 (12:07 ET) VOLUME(+): ONXX Volume 25% > 20-adsv, Stock +1.41% - Knobias
02/27/2003 (16:30 ET) Onyx Reports Fourth Quarter and Year-End 2002 Financial Results - PR Newswire
02/26/2003 (07:32 ET) CONF: ONXX To Present At 2003 BIO CEO Conference @ 10:30 ET - Knobias

JS200
FÜr alle noch Investierten resp. Interessierten !!!

RICHMOND, Calif., May 20 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced today that it will webcast a post-ASCO analyst briefing in New York City on June 4, 2003, beginning at 4:30 p.m. EDT. Clinical investigator, Keith T. Flaherty, M.D. of the University of Pennsylvania in Philadelphia and Ahmad Awada, M.D. of the Jules Bordet Institute in Brussels, will review recently reported clinical data for the RAF Kinase Inhibitor, BAY 43-9006, being developed in collaboration with Bayer Pharmaceuticals Corporation.

Hier wird sich wohl die weitere Kursentwicklung entscheiden.

Entweder Top oder Flop !!! ??? !!! ???:laugh: :mad: :laugh: :mad: :laugh: :mad:
Noch gibt es onxx im Sonderangebot !!!



Bis zum 4.Juni wird der Kurs weiter steigen !!!



Gruß BOCKNASE .............:laugh: ..:laugh: ..:laugh: ..:laugh: ..:laugh: ..:D
Novel RAF Kinase Inhibitor Bay 43-9006 Shows Early Signs of Tolerability and Activity in Phase Ib Combination Trials Reported at ASCO
Monday June 2, 11:22 am ET
Final Data from Phase I Single-Agent Studies also Presented


WEST HAVEN, Conn. and RICHMOND, Calif., June 2 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago encouraging Phase Ib data from two clinical trials of BAY 43-9006, a novel, investigational RAF kinase inhibitor, in combination with standard chemotherapeutics, as well as final Phase I results that confirm and extend the positive findings presented at international medical meetings in 2002. This novel inhibitor is an orally active small molecule agent currently in Phase II clinical development in a collaboration between Bayer and Onyx. The data describe safety findings and preliminary antitumor activity from multiple Phase Ib chemotherapy combination trials and Phase I single-agent clinical trials.
ADVERTISEMENT
AMERITRADE SPECIAL OFFER

· 30 commission-free trades
Start trading on us
· Command center screen
Get this FREE service
· Our 10-Second Guarantee
(restrictions apply)

Start getting your share with us
Open your account now





Phase Ib Clinical Study: BAY 43-9006 in Combination with Gemcitabine (Abstract 828)

Safety, pharmacokinetics and tumor response rate from a multicenter Phase Ib study of BAY 43-9006 in combination with gemcitabine were presented today in a poster presentation by Lillian L. Siu, M.D., of Princess Margaret Hospital in Toronto, Canada. The study was a dose-escalating Phase Ib trial, in which BAY 43-9006 was administered continuously at three different dose levels up to 400 mg twice daily, along with gemcitabine given at the standard dose of 1000 mg/m2. The patients had advanced solid tumors including pancreatic, colorectal, ovarian, esophageal, gastric, liposarcoma, nasopharyngeal and mesothelioma, for which no standard therapy exists and who were deemed suitable for treatment with gemcitabine chemotherapy. The safety results were reported in 20 patients treated on study. Hematological toxicities observed in the clinical data were non-dose limiting and consistent with gemcitabine effects. Non-hematological toxicities included decreased appetite, fatigue, hand-foot syndrome, skin rash, nausea and diarrhea. Only fatigue proved dose-limiting in one patient treated at the highest dose. Preliminary pharmacokinetic analysis revealed no significant interactions between BAY 43-9006 and gemcitabine. Data from 20 patients included one patient with a confirmed partial response in previously treated ovarian cancer, and disease stabilization of eight weeks or more in 11 patients with tumor types including: ovarian, pancreatic, colorectal, nasopharyngeal, and an unknown primary tumor. An expanded cohort of pancreatic cancer patients is currently being evaluated in this study.

Phase Ib Clinical Study: BAY 43-9006 in Combination with Carboplatin and Paclitaxel (Abstract 2854)

Data from a second chemotherapy combination Phase Ib study of BAY 43-9006 were presented Saturday, May 31, at an ASCO session devoted to melanoma and described in an announcement issued that day by the University of Pennsylvania. The multicenter, dose-escalating trial was designed to evaluate different dosage levels of BAY 43-9006 administered in combination with carboplatin and paclitaxel. Thus far, 20 patients with a variety of tumor types have been treated in the study. In an oral presentation, Keith T. Flaherty, M.D., of the University of Pennsylvania reported that BAY 43-9006 was well tolerated when combined with full dose carboplatin and paclitaxel. Toxicities, including skin rash and hand-foot syndrome, resolved themselves. No pharmacokinetic interaction between BAY 43-9006 and paclitaxel or carboplatin was reported. Dr. Flaherty reported confirmed partial responses in three of ten evaluable patients with melanoma, and disease stabilization in six additional melanoma patients, four of whom showed evidence of tumor necrosis.

"These trials are two of eight ongoing studies evaluating BAY 43-9006 in combination with a range of standard chemotherapeutic agents," stated Susan Kelley, M.D., Vice President of Oncology Product Development at Bayer Pharmaceuticals. "Further evaluation of BAY 43-9006 administered in combination with these cytotoxic drugs is warranted, based on these preliminary data. We are encouraged by the non-overlapping toxicity profiles and early indications of activity in the clinical setting."

Phase I Clinical Trials: Single-Agent BAY 43-9006 (Abstract 793)

Final data from single-agent Phase I clinical trials of BAY 43-9006 were presented today in a poster session by Dirk Strumberg, M.D., of the West German Cancer Center at the University of Essen. This report included data from four clinical Phase I single agent studies conducted at the University of Essen, the Jules Bordet Institute in Belgium, the Hamilton Regional Cancer Centre and Princess Margaret Hospital in Canada, and the Dana Farber Cancer Institute and the University of Southern California in the United States. In an analysis of 118 patients with advanced malignancies who received BAY 43-9006 doses of 200 mg twice daily or higher, 29 patients remained on BAY 43-9006 for more than six months, with no tumor progression or serious treatment-related adverse events. Of these, nine were on treatment for more than one year, with no disease progression or serious treatment-related adverse events. Durable partial responses were also observed in one liver cancer patient and one kidney cancer patient. Most of the dose-limiting toxicities were seen at dose levels of 600 mg twice daily or greater and included diarrhea and skin toxicity.

"These results from our now-completed single-agent Phase I program for BAY 43-9006 show signs of a favorable safety profile and preliminary antitumor activity," stated Dr. Kelley. "Phase II clinical trials are ongoing, and we are making preparations for the start of phase III."

About BAY 43-9006

BAY 43-9006 is a novel investigational compound directed against a specific molecular target involved in excess growth signaling in cancer. BAY 43-9006 blocks the enzyme RAF kinase, which is a critical component of the RAS pathway -- an important cascade of chemical signals that control cell division. Activating mutations of a RAS gene are estimated to occur in almost one-third of human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and 30 percent of non-small cell lung cancer. In addition, recent research suggests that a specific RAF kinase, BRAF, is activated by mutation in two-thirds of melanomas and smaller percentages of several other cancers.

The codevelopment collaboration between Onyx and Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States, where the companies can co-promote the product. Everywhere else in the world except Japan, Onyx`s share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds product development, and Onyx receives a royalty.

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 in codevelopment with Bayer. In addition, the company`s preclinical portfolio includes proprietary therapeutic viruses and Armed Therapeutic Virus(TM) products. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com .

About Bayer Pharmaceuticals Corporation

Bayer Pharmaceuticals Corporation is part of the worldwide operations of Bayer HealthCare, a subgroup of Bayer AG. Bayer HealthCare is one of the world`s leading innovators in the health care and medical products industry.

Bayer HealthCare combines the global activities of the business groups of Bayer AG in the fields of Biological Products, Consumer Care, Diagnostics, Animal Health and Pharmaceuticals. More than 34,000 employees support the worldwide operations of Bayer HealthCare.

Our work at Bayer HealthCare is to discover and manufacture innovative products for the purpose of improving human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer`s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including its Form 20-F) and Onyx`s public reports filed with the U.S. Securities and Exchange Commission (including its Form 10-K). The companies assume no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.




--------------------------------------------------------------------------------
Source: Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.
3:27PM Onyx Pharma -- Daily Breakout (ONXX) 12.88 +1.76: Shares of Onyx Pharmaceuticals are posting a 15.8% gain today. The $300 mln market-cap company is engaged in the development of novel cancer therapies utilizing two technology platforms, small molecules that inhibit the proteins involved in excess growth signaling, and therapeutic viruses that selectively replicate in cells with cancer-causing genetic mutations. The shares have broken to a new 52-week high today on 4.6x avg daily volume. Fundamentally, ONXX remains in the `develpmental stage` and continues to post operating losses. Earlier this week, the co. presented findings from early-stage studies that showed its cancer drug BAY 43-9006 was active against a several different cancers.
Nun wird es wohl aufwärts gehen in der nächsten Zeit!!

Onyx Pharmaceuticals upgraded to long term "buy"

Thursday, June 05, 2003 8:38:32 AM ET
CE Unterberg Towbin

NEW YORK, June 5 (New Ratings) — Analyst David Bouchey of CE Unteberg Towbin upgrades Onyx Pharmaceuticals (ONXX) to long term “buy” and issues a short term “market perform” rating. The 12-24-month target price is set to $17-$20.

A detailed report will follow.

Wir warten gespannt auf die Details !!

Gruß BOCKNASE

Briefing.com berichte:

3:31PM Top Weekly Performers : Stocks over $5 with the largest percentage gain this week include: INGN +118%; SFLK +43.2%;
ONXX +40.3%; AUGT +38.2%; SGMO +37.8%; VIRL +37.7%; IMCL +37.5%; APTI +37%; TALK +34%; SCOX +33.5%.

Damit kann sich ONXX durchaus sehen lassen.
Ich hatte ja bereits daraufhingewiesen, daß sich hier eine
positive Entwicklung in der nächsten Zeit einstellen wird.

Hoffen wir, daß es in der kommenden Woche so weiter geht.

MfG
Bocknase
Onyx to Focus Exclusively on Small Molecule Cancer Program
Wednesday June 11, 4:15 pm ET
BAY 43-9006 Takes Priority as Therapeutic Virus Program Is Discontinued


RICHMOND, Calif., June 11 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that the company is further prioritizing the clinical development of
BAY 43-9006, a novel anticancer compound expected to enter Phase III clinical testing later this year. Based on encouraging results to date from Phase I and Phase Ib clinical trials, the company, together with its partner Bayer Pharmaceuticals Corporation, intends to pursue multiple clinical paths with BAY 43-9006. As a result, Onyx will discontinue its therapeutic virus program, resulting in a reduction in force of approximately 50 of the company`s employees, most of whom were dedicated to the virus program. Following this reduction in force, Onyx`s remaining scientific and administrative personnel will be focused on furthering the development of BAY 43-9006. Onyx expects to record a restructuring charge related to this activity in the third quarter of this year. It is estimated that the company will save approximately $4 million on a quarterly basis. However, these savings are expected to be offset by increased clinical development expenses for BAY 43-9006 as the compound enters Phase III testing.

"Though the decision to close our therapeutic virus program was not an easy one, it was an appropriate business action," said Hollings Renton, Onyx`s chairman and chief executive officer. "BAY 43-9006 has continued to generate positive data in clinical trials, resulting in some difficult but necessary portfolio management choices."

Mr. Renton continued, "Without a corporate partner in the near term to share the investment needed to make meaningful progress in our therapeutic virus program, we cannot continue to fund this program as well as BAY 43-9006. At this point in time, it is important that we apportion our resources in a way that will most directly advance the commercialization of BAY 43-9006."

According to the codevelopment collaboration between Onyx and Bayer, Onyx funds 50 percent of the development costs for BAY 43-9006. In return, Onyx will share equally in any profits generated in the United States, where the companies can copromote the product. Everywhere else in the world, except Japan, Onyx`s share of any profits will be somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer will fund product development, and Onyx will receive a royalty based on any sales.

To date, BAY 43-9006 has been evaluated in hundreds of patients with cancer. Clinical trials include four completed Phase I single agent studies, eight ongoing Phase Ib studies combining BAY 43-9006 with different standard chemotherapies and two ongoing Phase II single agent studies. Final Phase I monotherapy results, along with data from two of the Phase Ib combination studies, were recently reported at the annual meeting of the American Society of Clinical Oncology (ASCO). Onyx and Bayer intend to conduct further clinical testing of BAY 43-9006, including a Phase III study planned for later this year.

Cancer is the second leading cause of death in the U.S. Despite its prevalence, many forms of cancer are inadequately treated with conventional approaches. Due to this large unmet medical need, BAY 43-9006 may have significant commercial potential across a number of tumor types -- either as a monotherapy or in tandem with current treatments with chemotherapeutic agents.

"Though we are winding down our therapeutic virus program, I have great faith in the ultimate potential of this novel approach. We are leaving open the option of restarting this program, either directly or in combination with outside investigators," said Mr. Renton. "Our employees have made important scientific progress in this area, and I thank them for their numerous contributions."

About Onyx Pharmaceuticals

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 in codevelopment with Bayer. For more information about Onyx`s pipeline and activities, visit the company`s website at www.onyx-pharm.com.

This news release contains forward-looking statements regarding expectations as to timing and amount of any restructuring charges; cost savings or clinical development expenses; the company`s plans as to the development of BAY 43-9006, including further clinical testing and the timing of such clinical trials; the company`s expectations or beliefs of the commercial potential of BAY 43-9006; and its plans with respect to strategic alternatives for its therapeutic virus program. These forward-looking statements involve a number of risks and uncertainties that could cause actual events to differ from the company`s expectations. These risks are addressed in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K filed on March 25, 2003 and its Quarterly Reports on Form 10-Q.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Aufgemerkt, ihr müden Biotech-Anleger !!!
Bei Onxx braut sich was zusammen. Das wird eine Kursrallye,
wie man sie nicht alle Tage zu sehen bekommt. Man ist
scheinbar in der Entwicklung eines bestimmten Produktes
einen großen Schritt weiter gekommen !!!!!

Gruß Bocknase
Sie steigt und steigt und steigt.....................
und keiner interessiert sich dafür !!!!!!!!!!!!!!!!!!

Wer zu spät kommt, den bestraft das Leben !!!!!!!!!!!

In diesem Sinne :laugh: schlaft alle ruhig weiter :O

Die große Überraschung steht erst noch bevor. Vielleicht
kommt dann mal jemand zufällig hier vorbei und ärgert sich
:mad: , daß er nicht eher munter geworden ist !!!!!!!!!!!!

Gruß BOCKNASE ;)

Schlafmützen aufgemerkt !!!!! das ist der Chart !!!!!

An diesem Bord fühlt man sich als Alleinunterhalter !
Aber nichts desto trotz, hier eine Meldung, die den Kursverlauf beeinflussen wird. Ob es zur lange erwarteten Initialzündung reichen wird, da kann man allerdings nur hoffen !!!!..........

:yawn: ........:yawn: ..........:yawn:


....................................................................................................................................................................................

RICHMOND, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will present at the UBS Global Life Sciences Conference in New York City on Monday, September 22, at 11:00 a.m. Eastern Time. Investors may access a live audio webcast of the presentation at http://event.streamx.us/event/default.asp?event=UBS20030922 . It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 jointly with Bayer Pharmaceuticals Corporation. For more information about Onyx`` pipeline and activities, visit the company``s web site at http://www.onyx-pharm.com/.

This news release contains forward-looking statements regarding expectations as to timing and amount of any restructuring charges; cost savings or clinical development expenses; the company``s plans as to the development of BAY 43-9006, including further clinical testing and the timing of such clinical trials; and the company``s expectations or beliefs of the commercial potential of BAY 43-9006. These forward-looking statements involve a number of risks and uncertainties that could cause actual events to differ from the company``s expectations. These risks are addressed in the company``s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K filed on March 25, 2003 and its Quarterly Reports on Form 10-Q.

Onyx Pharmaceuticals, Inc.

© PR Newswire
Morgen ist es soweit, dann wissen wir mehr.
Ein Kurssprung nach oben ist nicht auszuschließen. :kiss:

Gruß an mich selbst !!! ............... BOCKNASE
@bocknase

zuerst,ich war und bin ein langjähriger optimist von onyx.
ich freue mich für alle investierten.leider war ich aus persönlichen gründen vor einigen monaten ausgestiegen.meine frage an dich,sollte nicht schon letztes jahr onyx o15 auf den markt kommen?
kannst du mich über die letzen infos informieren,
und was erwartestdu gleich von der conference?rt -4,1%
@JK

Habe leider über die Ergebnisse der Konferenz nichts erfahren, aber der weiter steigende Kurs und der ungebrochene kontinuierliche Drang nach oben zeigt, daß sehr große Erwartungen mit Onyx verbunden werden, wobei ich die Hoffnung habe, daß der eigentliche Kurssprung erst noch beforsteht.

MfG BOCKNASE
@Bocknase

bin seit 2000 in ONXX investiert auch PDLI usw. Was soll ich sagen, der erste Wert mit dem ich jetzt 30% im Plus bin ist ist ONXX. Es ist allerdings sehr schwer, Informationen zu erhalten, der Kursanstieg beständig und ohne News kann viel bedeuten. Der Umsatz ist sehr hoch in den letzten Monaten und das deutet auf Investments hin. Bis Dezember könnte der Kurs weiter laufen oder bei enttäuschenden Nachrichten auch einbrechen. Werde die Zeit heute nutzen und versuchen auf den Ami-Boards neuigkeiten zu erfahren. Gibt es eigentlich in Germony noch einen Biorech-Stock-report der was taugt?

Gruß RTL
Die Erklärung für den ständigen Drang nach oben könnte
zum Beispiel hier zu finden sein !

08.09.2003
Onyx Pharma. spekulativer Kauf
sunday-biotech

Dem spekulativ ausgerichteten Anleger empfehlen derzeit die Analysten von "sunday-biotech" die Aktien von Onyx Pharmaceuticals (ISIN US6833991093/ WKN 900778) zum Einstieg.

In einer gemeinsamen Entwicklung hätten das amerikanische Biotech-Unternehmen Onyx und die deutsche Bayer eine "BAY 43-9006" genannte Substanz gefunden, die ein Enzym aus dem Ras-Regelmechanismus blockiere und damit die Bildung von Tumorzellen verhindere. Die klinischen Ergebnisse mit BAY 43-9006 seien, soweit bekannt, vielversprechend. Die endgültigen Daten einer Phase II-Studie würden noch ausstehen. Dennoch bereite Bayer bereits eine entscheidende Phase III-Prüfung an Patienten mit Leberkarzinomen vor, die möglicherweise noch dieses Jahr beginnen solle. Dies spreche für ein großes Vertrauen beider Unternehmen in die Wirksamkeit des Mittels.

Onyx werde aktuell mit gut 400 Millionen US-Dollar bewertet. Zur Abschätzung des Kurspotenzials nehme "sunday-biotech" an, mit dem neuen Tumormittel werde ein Umsatz von 300 bis 500 Millionen US-Dollar gemacht, von dem Onyx rund 50 Prozent erhalte. Bei den üblichen Kurs-Umsatz-Verhältnissen zwischen 3 und 5 würde Onyx danach eine faire Bewertung zwischen 500 bis 1.000 Millionen US-Dollar zustehen. Schwer einzuschätzen sei jedoch die Gefahr des Scheiterns, die die augenblickliche Bewertung vernünftigerweise auf ein Bruchteil reduziere. Erweise sich BAY 43-9006 als Fehlschlag, werde sich der Kurs von Onyx zusammenfalten.

Wen allerdings das Kurspotenzial reize und das hohe Risiko nicht schrecke, der kann sich nach Ansicht der Analysten von "sunday-biotech" einige Stücke von Onyx als spekulative Beimischung ins Depot holen.

Also, nicht lange zögern und zuschlagen, ehe der Kurs sich
nochmal verdoppelt hat !!!

MfG BOCKNASE
FinanzNachrichten.de, 14.10.2003 23:10:00

Onyx Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference


RICHMOND, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will present at the Rodman & Renshaw Techvest Healthcare Conference in Boston on Wednesday, October 22 at 12:40 p.m. Eastern Time. Investors may access a live audio webcast of the presentation at:

http://www.rodmanandrenshaw.com/rodman.asp?link=usschedule&bgcolor=wht

by clicking on the Onyx Pharmaceuticals link and following the directions. It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. If you are unable to participate during the live webcast, recorded replays of the presentation will be available shortly after the presentation is completed through November 14.

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its partners, the company is developing small molecule drugs, including BAY 43-9006 with Bayer Pharmaceuticals Corporation. For more information about Onyx`` pipeline and activities, visit the company``s web site at http://www.onyx-pharm.com/.

Onyx Pharmaceuticals, Inc.

© PR Newswire

Mal sehen, ob da ein Kursbeschleuniger auf der Konferenz rausgelassen wird.
Es wäre sehr gut denkbar.

MfG
BOCKNASE
Onyx Pharmaceuticals Receives $15 Million Milestone Payment From Bayer
Thursday December 18, 7:00 am ET
Milestone Achieved with Initiation of Phase III Clinical Trial


RICHMOND, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that it has received a $15 million creditable milestone-based payment from Bayer Pharmaceuticals Corporation related to the development of BAY 43-9006, a novel anti-cancer compound, which the two companies are co-developing. The milestone was achieved upon the previously announced initiation of the first Phase III clinical trial for BAY 43-9006.
ADVERTISEMENT


This is the second milestone payment Onyx has received from Bayer. The first payment of $5 million was paid when the two companies began the first Phase II trial of BAY 43-9006 in 2002. In addition, Onyx can achieve two more milestones, each triggering a creditable milestone-based payment from Bayer of $10 million. The first of these milestones is the filing of a New Drug Application (NDA), and the second is the approval of BAY 43-9006 in any one of the United States, Germany, Italy, Spain or the United Kingdom. All milestone payments are repayable to Bayer from a portion of Onyx`s future profits and royalties.

BAY 43-9006 is an orally active small molecule in Phase III clinical testing for patients with advanced renal cancer. The compound is also being studied in two ongoing Phase II trials, as well as eight Phase Ib studies evaluating its use in combination with standard chemotherapeutics. This novel signal transduction inhibitor has a dual mechanism of action, targeting both cell proliferation and angiogenesis (formation of blood vessels). By inhibiting RAF kinase, BAY 43-9006 blocks the RAS/MEK/ERK signaling pathway in cells, an important mediator of tumor cell proliferation. BAY 43-9006 also exerts an anti-angiogenic effect, which could come from both direct effects on the VEGFR-2 and PDGFR-beta receptors, as well as from downstream effects on RAF kinase.

Under the co-development agreement between Bayer and Onyx, Onyx funds 50 percent of the development costs for BAY 43-9006. In return, Onyx will have a 50/50 profit share in the United States, if it elects to co-promote the product and continues to fund development costs. Everywhere else in the world, except Japan, Bayer has exclusive marketing rights, and Onyx`s share of any profits will be less than 50 percent. In Japan, Bayer will fund all product development, and Onyx will receive a royalty on any product sales.

Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its partners, the company is developing small molecule drugs, including BAY 43-9006 with Bayer Pharmaceuticals Corporation. For more information about Onyx`s pipeline and activities, visit the company`s web site at www.onyx-pharm.com.

This news release contains forward-looking statements regarding expectations as to the company`s plans as to the development of BAY 43-9006, including further clinical testing and the timing of clinical trials; the receipt of creditable milestone-based payments; the company`s expectations or beliefs of the commercial potential of BAY 43-9006; and the mechanisms of action for BAY 43-9006. These forward-looking statements involve a number of risks and uncertainties that could cause actual events to differ from the company`s expectations. These risks are addressed in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K filed on March 25, 2003 and its Quarterly Reports on Form 10-Q.




--------------------------------------------------------------------------------
Source: Onyx Pharmaceuticals, Inc.
Habe es auch gerade per email von ONXX erhalten.
Es kann ja nur gut sein, wenn wieder Geld in die
Kasse gespült wird.
Vielleicht kommt damit auch wieder etwas mehr Schwung
in den Kurs !!!

MfG
BOCKNASE .................
:rolleyes: .........:rolleyes: ..........:rolleyes: ......
Anscheinend bin ich an diesem Bord ein Alleinunterhalter.
Ich wollte nur mal wieder auf den ungebrochenen Aufwärtstrend
bei ONXX hinweisen. Ich habe das ja bereits in früheren
Beiträgen prognostiziert. Aber es scheint sich niemand für
Kursgewinne zu interessieren.
Hier nochmal der Chart zur Information:



Der Trend wird weiter anhalten! Noch stehen wir vor der
eigentlichen Explosion !!

MfG
Bocknase
RealCommentary from TheStreet.com
Onyx Ups the Ante on Skin-Cancer Drug
Thursday January 29, 11:28 am ET

By Adam Feuerstein, TheStreet.com Senior Writer

Onyx Pharmaceuticals (NasdaqNM:ONXX - News) is expanding an early-stage skin-cancer study involving its experimental drug BAY 43-9006 -- a confirmation that preliminary, positive results released last year continue to hold up.

Onyx has been a red-hot biotech stock for well over a year, on the basis of BAY 43-9006`s potential to become a new and novel cancer-fighting drug. Most of the investor attention has been focused on efforts by Onyx and partner Bayer (NYSE:BAY - News) to get the drug approved as a treatment for advanced kidney cancer. (A Food and Drug Administration filing could come as early as this spring; more on that below.)
Hallo Bocknase !!

Wollte Dir eigentlich schon lange mal mailen, nur war ich
da noch nicht registriert.
Weißt du warum der Kurs so rasant gestiegen ist, möchte mir unbedingt
die ONYX ins Depot legen !!
Würdest du zu diesem Kurs momentan noch einsteigen !

Würde mich auf eine Antwort von dir freuen !

mfg ONYX
# Onyxleader

Das ist die letzte Information, die ich gefunden habe:

Onyx Pharmaceuticals (ONXX: news, chart, profile) is another of Jenner`s favorites.

The company is partnering with Bayer Pharmaceuticals to develop a drug to treat renal cell carcinoma, late stage melanoma and other cancers. The drug could receive FDA approval within the next 18 month, Jenner said.

Onyx is relatively high-risk investment, he noted. "If the clinical trials do not unfold as I believe they will, this company really doesn`t have much else."

The fund acquired Onyx shares at an average cost in the "mid- to high-teens," Jenner said. His 12-month share-price target is $50, he added.

Die Erwartungen, daß es ONXX in Zusammenarbeit mit Bayer gelingen
wird, ein wirksames Krebsmedikament zu entwickeln, liegen,
offensichtlich nicht ohne Grund, sehr hoch.
Ich rechne deshalb damit, daß es kurz vor Bekanntgabe der Ergebnisse noch einmal zu einem rasanten Kursanstieg, etwa einer Verdopplung des Kurses, kommen könnte.
Was danach kommt, das wissen die Götter, das hängt natürlich ganz wesentlich von den Ergebnissen ab.

MfG
BOCKNASE
Hi Bocknase !!

Vielen Dank für deine Email, dachte schon dich gibt es nicht
mehr.
Interssante Neuigkeiten von ONYX !!

Wann ungefähr konnen da Neuigkeiten raus, Versammlung
etc.... ?
Wird dies heuer noch alles passieren ?
Welches Kursziel siehst du für dieses Jahr für die Aktie ?

Momentan liegt die Aktie immer noch voll im Aufwärtskanal !!
Würdest du die Aktie jetzt noch kaufen ?

Gott Sei Dank gibt es dich, denn all die anderen
haben scheinbar auf die tolle Aktie keinen Bock.

mfg. ONYX
Hier in aller Eile eine aufschlußreiche Meldung!

Onxx und Bayer arbeiten bekanntlich zusammen.

05.04.04 19:18
WEST HAVEN (dpa-AFX) - Der Chemie- und Pharmakonzern Bayer AG hat von der US-amerikanischen Gesundheitsbehörde FDA den beschleunigten Zulassungsstatus für sein Krebsmedikament BAY 43-9006 erhalten. Dies teilte der Konzern am Montag zusammen mit seinem Partner Onyx Pharmaceuticals in West Haven mit. Das neue Präparat soll zur Krebsbehandlung eingesetzt werden. Der RAF-Kinase und VEGF-Hemmer befindet sich in der klinischen Prüfung (Phase III). Das Präparat ist einer der neuen Hoffnungsträger des Bayer-Pharmageschäftes. /jha/ck



BAY.MIX BAY.ETR

Quelle: News (c) dpa-AFX Wirtschaftsnachrichten GmbH.

MfG
Bocknase
Hi Bocknase !!!

Habe ich auch auf N-TV gehört !
Aber warum steigt denn der Kurs mit diesen News nicht mit an ?
Hat dies der Kurs schon scheinbar zuvor weg genommen ??
Dein persönliches Kursziel für 2004 ??


mfg. ONYX
Ich denke mal, da war schon etwas vorweggenommen. Allerdings glaube ich schon, daß der Aufwärtstrend dem bisherigen Chartverlauf folgend, noch einige Zeit anhält. Die Phase III läuft ja noch einige Zeit, wie lange genau, weiß ich auch nicht. Nur sollte man dann vor Ablauf genau beobachten und recherchieren, wie groß eventuell die Erfolgsaussichten sind. Offensichtlich müssen sie wohl doch sehr gut sein, anders kann ich mir den langanhaltenden Kursverlauf nicht erklären. Was ich länger beobachtet habe, es werden fast ausschließlich kleine Stückzahlen gehandelt. Ob sich da jemand, der mehr weiß, als wir, kontinuierlich eindeckt, oder ob das alles Kleinanleger sind, die lediglich die Hoffnung auf Erfolg treibt, das ist schwer einzuschätzen.
Ich hoffe einfach mal, daß sich der Kurs vor den Phase III-Ergebnissen noch bis 80 oder 100$ entwickelt. In dem Falle würde ich dann vor Bekanntgabe sicherheitshalber aussteigen, denn dann hätte sich mein Depot verfünffacht und
damit wäre ich sehr zufrieden.

Ein frohes Osterfest und weiterhin steigende Kurse

MfG
Bocknase
Hi Bocknase !!!

Danke für dein Mail, ist immer wieder interssant, was
du so schreibst. Dann halten wir die gute noch ein
oder zwei Jahre.
Wieviel Stück, und zu welchem Kurs bist du eingestiegen ?
Hast scheinbar echt einen günstigen Zeitpunkt erwischt !

Aber du beschäftigst dich ja auch schon seit jeh mit der Aktie.
Habe deine Mails alle gelesen. Echt super, vielen Dank !

Wünsche dir auch ein frohes Osterfest und bald die 100 Dollar !!

Servus ONYX
Reuters
OSI, Millennium, Onyx shares seen rising-Barron`s
Sunday April 18, 4:35 pm ET


NEW YORK, April 18 (Reuters) - Stocks of small biotechnology companies are poised to advance beyond its recent run-up on prospects about licensing deals and acquisitions, Barron`s reported in its latest issue.
ADVERTISEMENT


Big pharmaceutical groups are looking for small, promising biotech companies to drive growth as some of their top-selling drugs lose patent protection in the next couple of years, according to the article.

Morgan Stanley biotech analyst Steve Harr told Barron`s he is focusing on companies with new treatments for the toughest medical problems, like cancer. Among them are OSI Pharmaceuticals Inc. (NasdaqNM:OSIP - News), Millennium Pharmaceuticals Inc.(NasdaqNM:MLNM - News) and Onyx Pharmaceuticals Inc. (NasdaqNM:ONXX - News).

Harr also anticipates that a successful treatment for an eye disease could boost the stock of Eyetech Pharmaceuticals Inc. (NasdaqNM:EYET - News) to $42. Eyetech closed at $33.49 on Friday.

On Friday Nasdaq trade, OSI Pharmaceuticals closed at $36.20, Millennium ended at $16.88, and Onyx finished at $43.25.

Harr said he does not own shares in the biotech companies he covers, but his firm has done investment banking work for them.
Hallo Jungs und Mädels !!

Michwürde immer noch euere Meinung zu ONYX
interssieren. Schaut euch mal den super Kursverlauf an !!

Wie gehts weiter, was meint ihr !!

Servus ONYX
Hallo !!!

Habe gerade gelesen, daß für ONYX ein Kursziel von
61 Dollar herausgegeben wurde.

Tschau ONYX
Hallo !

Hätte mal eine Frage an euch, was denkt ihr, wie es
mit ONYX nach dem rasanten Kursrückgang weiter geht ?
Eine gesunde Korrektur, oder mehr ?
Wo steht momentan der Amex ?
Wo kann ich den Chart vom Amex nach voll ziehen ?

mfg. ONYX
Reuters
Bayer, Onyx drug shrinks tumors in some patients
Saturday June 5, 8:45 am ET
By Jed Seltzer


NEW YORK, June 5 (Reuters) - About 35 percent of patients on an experimental drug being developed by Bayer AG (XETRA:BAYG.DE - News) and Onyx Pharmaceuticals (NasdaqNM:ONXX - News) experienced a reduction in their kidney cancer tumors of 25 percent within three months, researchers said on Saturday.
The results are significant because the drug, sorafenib, could provide a less-toxic treatment alternative than drugs currently used for kidney cancer, also known as renal cell cancer. In addition, the drug is a pill, as opposed to injections that are often used to treat kidney cancer.

The experimental drug was tested in a mid-stage, or Phase II clinical trial of 106 kidney-cancer patients. Of those 106 patients, 37 saw their tumors shrink by 25 percent or more in the first 12 weeks of treatment and 45 had their disease "stabilize" -- meaning tumors shrank less than 25 percent or grew no more than 25 percent.

The clinical trial, which was presented at an annual meeting of the American Society of Clinical Oncology, did not compare the drug to any other therapy.

Patients whose tumor progress "stabilized" after 12 weeks were then randomized and given either the drug or a placebo. Results from the progress of those patients -- which could be important to uncovering the drug`s true effectiveness -- could be available this summer or fall.

Onyx, a small biotechnology company, and German drugmaker Bayer intend to enroll a total of 800 patients in a Phase III clinical trial.

Sorafenib, known as BAY 43-9006 for Bayer`s development purposes, is a member of the new category of drugs generally known as anti-angiogenesis inhibitors, designed to starve tumors of the blood they need to thrive.

The drug blocks a blood-vessel promoter, Raf kinase, an enzyme that acts as a control switch for the RAF gene, which helps control tumor growth. It has also been shown to block a protein called Vascular Endothelial Growth Factor, which plays a key role in the growth of blood vessels.

Dr. Mark Ratain, a University of Chicago researcher who was the primary investigator for the trial, said he envisions the oral treatment being used as a chronic-care drug, with patients being monitored often to see if their disease has progressed to the point where they need more serious therapy.

"It is not going to be a cure and it is not going to result in long-term disease survival," he said. "But it is potentially an appropriate first-line therapy."

Drugs currently used for cases of serious kidney cancer include interferons, or injected versions of proteins that the body uses to fight viruses, or interleukin-2, a cellular hormone normally produced by white cells that is central to the functioning of the human immune system, including the rejection or destruction of tumor cells.

Both drugs are considered heavy-duty and can be toxic.

Of the patients who had the most robust response -- 25 percent tumor reduction or greater -- the median time before the disease progressed again was 48 weeks, a delay Ratain considers strong, if not outstanding.
Hi Panik !!

Was steht da alles drinnen, kann es nur so halb wegs
übersetzen. Dem Kursverlauf nicht s positives !!

mfg. ONYX
Hallo !!!

Wer von euch kann mir sagen, ob sich Onyx noch in einem Aufwärtstrend befindet ? Oder wo der Trend demnächst hinzeigt. Oder nur kurzer Durchhänger ?!

Bitte um eure Infos, Meinungen, Anregungen !

mfg. ONYX
Hallo Biotechler !!

Wer kann mir etwas über den Chart Verlauf von ONYX
sagen ?
Falls mir doch irgendwann mal jemand antworten sollte !!

Danke !

mfg. ONYX
Hallo Biotechler !!

Wer kann mir etwas über den Chart Verlauf von ONYX
sagen ?
Falls mir doch irgendwann mal jemand antworten sollte !!

Danke !

mfg. ONYX
Hi Jungs und Mädels !!

Wie sieht es jetzt mit der Aktie ONYX aus ?
Die hat ja die 38 und die 200 Tages Linie durch-
brochen !!

Würde mich über euere Meinungen und Mails sehr
freuen.

mfg. ONYX
@onyxleader

wenn du eben rtl aktuell gesehen haben soltest,dann hast du sicher mitbekommen das sie onyx erwähnt haben.
nicht direkt,aber bay 43-9006.

ich sach mal es sieht gut aus,sehr gut.:D
hallo jk.
habe den bericht nicht gesehen,kannst du mir sagen um was es ging ??

danke
@asics01

den ganzen bericht habe ich leider nicht mitbekommen,hörte aber wie das man von einem durchbruch bei krebs sprach.
bay-43-9006 stehe kurz vor der zulassung in den usa.und das man sehr gute erfolge bei patienten erreichte.
der krebs würde nicht verschwinden,aber gestoppt.

ich bin leider schon lange nicht mehr in onyx,(aber sie gehörte mal zu meinen lieblingen)
verständlich das ich dadurch nicht gezielter antworten kann.
als sie bay 43-9006 erwähnten wusste ich gleich das es um onyx ging.
und wenn es bei rtl aktuell erwähnt wird,als durchbruch beim krebs,dann kann es nicht schlecht sein.

die zulassung beschränckte sich auf den nierenkrebs,aber man könnte es noch auf andere richtungen übertragen.
welche kann ich leider jetzt nicht sagen,weil wie erwähnt habe ich nicht den ganzen bericht in ruhe sehen können.

denke ihr könnt was danit anfangen,

viel glück

jk.
sorry,

sie stelten noch einen patienten vor,der täglich seine pille nehmen muüsse aber dafür sehr gut weiter leben könne
Hi JK !!

Vielen Dank für deine Mails !
Hört sich ja relativ gut an !
Vielleicht sehen wir ja irgendwann mal wieder
die 50 Euro Marke !!!

mfg. ONYX
liest27.10. 13:54
Bayer - BAY 43-9006 erhält Orphan Drug Status

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Die Bayer HealthCare Division Pharma und Onyx Pharmaceuticals haben von der Food and Drug Administration (FDA) für BAY 43-9006 den Orphan Drug Status zur Behandlung des Nierenzellkarzinoms erhalten, dies teilte der Chemie- und Pharmakonzern Bayer heute mit. Die Substanz wird gegenwärtig in der Behandlung des metastasierenden Nierenzellkarzinoms untersucht. In der EU wurde dem Bayer Medikament dieser Status bereits zuerkannt. BAY 43-9006 befindet sich gegenwärtig in der Phase III der klinischen Prüfung. Das Präparat wurde gemeinsam von Bayer und Onyx entwickelt.

Durch den Orphan Drug Status der FDA erhalten die Unternehmen Vergünstigungen, die Medikamente gegen Krankheiten entwickeln, von denen in den USA weniger als 200000 Patienten betroffen sind.

"Dieser Status ist für Bayer und Onyx ein weiterer wichtiger Schritt in der Entwicklung von BAY 43-9006", sagte dazu Dr. Susan Kelley, Leiterin des Forschungsbereichs Onkologie bei der Bayer HealthCare Division Pharma. BAY 43-9006 erhielt kürzlich auch den sogenannten Fast Track Status. Beide Klassifizierungen ermöglichen eine häufigere Kommunikation mit der FDA. Dadurch könne die Entwicklung, die Prüfung und die Bearbeitung des Zulassungsantrags effektiver vorangebracht werden.
HI ASICS01 !!

Das sind doch alles super News !!
Warum dann der rapide Kurssturz ?

Was meinst du, erholt sich die Aktie wieder schnell von dem Kurssturz ?

Was sagt denn der Chart aus ?
Die 38 und die 200 Tage Linie sind ja Meilen weit erfernt !?

Servus ONYX
Zumindest hier spricht man von Flop der Phase II....

Nach Ansicht der Landesbank Rheinland-Pfalz (LRP) sollte man die Studienergebnisse für das Nierenkrebsmedikament, welches Bayer mit dem US-Unternehmen Onyx entwickelt, nicht überbewerten. Die Daten der klinischen Phase II wurden von einigen Investoren enttäuscht aufgenommen, die Aktie der Onyx Pharmaceuticals brach am Montag um fast 30% ein. Bayer notieren am Dienstagvormittag gut 1% im Minus. LRP-Analystin Silke Stegemann sieht die Ergebnisse gelassen. Für Bayer hätten sie keine "gewaltigen Auswirkungen",sagt Stegemann im Gespräch mit Dow Jonesnews.

Das Nierenkrebsmedikament sei bei Bayer nur eines von vielen. Der Konzern habe noch viele anderen Entwicklungen in der Pipeline und sei breit genug aufgestellt. Die Kooperation mit Onyx sei nur ein kleiner Baustein, sagt Stegemann......

(ENDE) Dow Jones Newswires/26.10.2004/ves/ps
02.11. 16:01
Bayer/Onyx: Krebswirkstoff unbedenklich

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Bayer und Entwicklungspartner Onyx Pharmaceuticals haben heute einen Testerfolg für ihren Krebswirkstoff BAY 43-9006 gemeldet. Wie mehrere Tests der klinischen Phase I erbracht hätten, könne der Tumorwachstums-Hemmer offenbar bedenkenlos in Kombination mit klassischer Chemotherapie verabreicht werden. Es seien dabei keine unerwarteten Neben- und Wechselwirkungen aufgetreten.

Die Bayer-Aktie liegt im Xetra-Handel derzeit 0,58 Prozent im Plus bei 22,67 Euro; Onyx Pharma gewinnen an der Nasdaq 2,46 Prozent auf 27,96 Dollar hinzu.
kann ja wohl so schlecht nicht sein oder ??
Hi ASICS !!

Da hast du recht, das Zeug ist bestimmt gut !!
Da waren bestimmt wieder nur ein paar Millionäre da,
die Panik geschoben haben und ein paar Aktien verkauft haben !!!

Aber ich halte an meinen Papieren fest, denn die Aussichten sind nach wie vor nicht schlecht und bei dem Niveau würde ich am liebsten einsteigen, aber leider baue
ich gerade Haus und da habe ich halt keinen Pfennig über !

Was denkst du darüber ??

mfg. ONYX

PS: Mit dem Chart komme ich nicht ganz so klar, kannst du da mir was dazu sagen ??!!
Hi Leute !!!

Wer weiss denn mal wieder was neues über
ONYX ?
Wer kennt sich mit dem Chart aus, und kann mir da
was sagen ?
Welche Tendenzen strebt den der AMEX Biotech an ?

Würde mich über Neuigkeiten freuen !

mfg. ONYX
Sehr viele Käufer in der letzten Handelsstunde.. vieleicht gehts morgen so weiter. Der erhöhte Umsatz würde ja schon fast dafür sprechen.

Gruss
Macros
Hi Macros !!!

Da hätte ich bestimmt nichts dagegen gehabt, aber
wie es aussieht, schliessen wir heute wieder mal im
Minus !
Naja, zur Zeit tut sich relativ wenig, dümppelt halt so vor sich hin.
Die Ruhe vor dem Weihnachtssturm !!
Der Glaube versetzt Berge !
Was ist eigentlich dein persönliches Kursziel für die
nächsten 2 Jahre`??

mfg. ONYX
Hallo !

Was ist denn mit der lieben ONYX los ?
Wer weiss denn da mehr ?

Wo ist denn die Talfahrt zu Ende ?
Welche Grenzen gibt es ?

Merci !

mfg. ONYX
hallo onyxleader
lang nichts mehr von dir gehört.zur zeit verprügeln die amis die bios wieder, fundamental nicht nachzuvollziehen.gut es gab jede menge schlechte news aber das rechtfertigt diese kursverluste der ganzen branche nicht.aber wenn du bei onyx einen langen atem hast wirst du der sein der zuletzt lacht.die verluste tun schon weh, aber du hast erst verluste gemacht wenn du verkaufst.wird schon werden wenns auch manchmal schwer fällt dran zuglauben.
asics
hallo onyxleader
wo steht denn dein einstiegskurs und wie lange hälst du onxy´schon ??
asics
Hi ASICS !!

Bei ca. 30 Euro !
Die habe ich schon lange ca. 3- bis 4 Jahre !

Wie wird es mit denen weiter gehen ?
Was meinst du denn ?

Ich dachte, unter 70 Dollar gebe ich die nicht wieder her ?

Was sagst denn zur aktuellen Lage ?

Schönes Wochenende

mfg. ONYX
im 2 ten quartal wollen onyx ergebnisse der phase 3 studie ihres BAY 43-9006 veröffentlichen,wenn die gut sind wird man ganz schnell neue höchstkurse sehen.
asics
Hi Biotechler !!!

Kann mir jemand was neues von ONYX sagen ?

Wie ist die Aktie cahrttechnisch zu bewerten ?

Vielen Dank für euere Antworten schon mal im voraus !

mfg. ONYX
Antwort auf Beitrag Nr.: 21.353.519 von ONYXLeader am 27.04.06 20:51:31Hallo miteinander !
Endlich erholt sich ONYX mal wieder ein bißchen.
Vielleicht ist jetzt die Durststrecke vorbei ?

Wer weiß dazu was neues ?
Gibt es positive Neuigkeiten zu den Medikamenten ?

Vielen Dank für Euere Antworten.

Servus ONYX:yawn:
Hallo Biotechler !

Interessiert sich denn keine Sau für das gute Ding ?
ONYX steigt und steigt !
Wo gehts denn hin !

Hallo meldet euch mal !
Würde mcih sehr freuen

Servus ONYX:kiss:
hallo onyxleader
bist du immer noch mit von der partie??sei doch froh dass onyx nicht so gepuscht wird,ist doch viel besser so.onyx ist gut gib ihr noch etwas zeit zum reifen,die wird ihren weg schon machen.
asics:keks:
Hi Ascics !!

Schön von Dir zu hören.
Na klar, ich binimmer noch in ONYX investiert.
Ich hoffe, das ONYX diesen Weg weiter nach oben geht.
Was meinst du ?
Wie sieht es damit aus, gibt es NEWS ?
Bei 100 Dollar verkaufe ich !
Und du !

Gruss ONYX:rolleyes: